RESEARCH ARTICLE

Application of two-dimensional difference gel electrophoresis to identify protein changes between center, margin, and adjacent non-tumor tissues obtained from non-small-cell lung cancer with adenocarcinoma or squamous cell carcinoma subtype

Andrzej Ciereszko<sup>1</sup>*, Mariola A. Dietrich<sup>1</sup>, Mariola Słowińska<sup>1</sup>, Joanna Nynca<sup>1</sup>, Michał Ciborowski<sup>2</sup>, Monika M. Kaczmarek<sup>3</sup>, Kamil Myszyński<sup>3</sup>, Joanna Kiślik<sup>4</sup>, Anna Majewska<sup>1</sup>, Anna Michalska-Falkowska<sup>6</sup>, Natalia Kodzik<sup>3</sup>, Joanna Reszeć<sup>3</sup>, Ewa Sierko<sup>6</sup>, Jacek Nikliński<sup>4</sup>

<sup>1</sup>Department of Gametes and Embryo Biology, Institute of Animal Reproduction and Food Research, Polish Academy of Sciences, Olsztyn, Poland, 2 Metabolomics Laboratory, Clinical Research Centre, Medical University of Białystok, Białystok, Poland, 3 Molecular Biology Laboratory, Institute of Animal Reproduction and Food Research Polish Academy of Sciences, Olsztyn, Poland, 4 Department of Clinical Molecular Biology, Medical University of Białystok, Białystok, Poland, 5 Department of Medical Pathomorphology, Medical University of Białystok, Białystok, Poland, 6 Department of Oncology, Medical University of Białystok, Białystok, Poland

* a.ciereszko@pan.olsztyn.pl

Abstract

Lung cancer is responsible for the most cancer-related mortality worldwide and the mechanism of its development is poorly understood. Proteomics has become a powerful tool offering vital knowledge related to cancer development. Using a two-dimensional difference gel electrophoresis (2D-DIGE) approach, we sought to compare tissue samples from non-small-cell lung cancer (NSCLC) patients taken from the tumor center and tumor margin. Two subtypes of NSCLC, adenocarcinoma (ADC) and squamous cell carcinoma (SCC) were compared. Data are available via ProteomeXchange with identifier PXD032736 and PXD032962 for ADC and SCC, respectively. For ADC proteins, 26 significant canonical pathways were identified, including Rho signaling pathways, a semaphorin neuronal repulsive signaling pathway, and epithelial adherens junction signaling. For SCC proteins, nine significant canonical pathways were identified, including hypoxia-inducible factor-1α signaling, thyroid hormone biosynthesis, and phagosome maturation. Proteins differentiating the tumor center and tumor margin were linked to cancer invasion and progression, including cell migration, adhesion and invasion, cytoskeletal structure, protein folding, anaerobic metabolism, tumor angiogenesis, EMC transition, epithelial adherens junctions, and inflammatory responses. In conclusion, we identified several proteins that are important for the better characterization of tumor development and molecular specificity of both lung cancer subtypes. We also identified proteins that may be important as biomarkers and/or targets for anticancer therapy.
Introduction

Cancer is the leading cause of human mortality. Among cancers, lung cancer is the most common in the world and responsible for the most cancer-related mortality worldwide [1]. Non-small-cell lung cancer (NSCLC), the most common type of lung cancer (85% of cases), can be divided into three main subgroups: adenocarcinoma (ADC, 30–50% of cases), squamous cell carcinoma (SCC, ~30%), and large cell carcinoma (LCC, ~10%) [2]. The prevention of lung cancer is still a great challenge. The symptoms of lung cancer are usually very difficult to recognize until the disease has reached an advanced, non-curable state. Late diagnosis is a significant factor contributing to the poor prognosis for lung cancer [1]. It is estimated that only 16% of patients survive for five or more years after diagnosis. For this reason, the development of biomarkers for effective prognosis is of utmost importance [3].

Biomarkers are biological compounds that can be used to distinguish pathology from normal status. At the molecular level, proteins represent the most important functional unit that is directly responsible for a phenotype. For this reason, almost all the Food and Drug Administration approved cancer biomarkers are proteins [4]. Unfortunately, the number of potential protein markers is very limited and, at present, restricted to a few proteins, such as cytokeratin 19 fragments (CYFRA 21–1), carcinoembryonic antigen, SCC antigen, neuron-specific enolase, progastrin-releasing peptide, and epidermal growth factor receptor [1]. The most common approach for discovering new markers is to analyze proteins overexpressed in lung cancer tissue and use this knowledge to select prospective cancer markers [5, 6].

The proteome is defined as the total proteins expressed by a genome, including their numerous different forms (proteoforms) produced by post-translational modifications (PTMs). Proteomics has become a very powerful tool for studies of proteomes in relation to cancer, and among the methodical approaches, those based on two-dimensional electrophoresis (2DE) have proven especially useful [7]. Two-dimensional difference gel electrophoresis (2D-DIGE) is variation of 2DE and includes steps such as pre-electrophoretic fluorescent labelling, electrophoretic separation in the first dimension using electrofocusing, electrophoretic separation in the second dimension using SDS-PAGE, protein spot detection using the scanning of gels at three wavelengths to detect different fluorophores, and intragel comparisons with image analysis programs to evaluate differentially expressed proteins [8]. 2D-DIGE has become the favored method for the proteomic analysis of lung cancer due to its high reproducibility, high sensitivity, comprehensiveness, and high throughput [9, 10]. We recently successfully used 2D-DIGE for the identification of protein changes in the blood plasma of lung cancer patients subjected to chemotherapy [11]. Due to the extreme complexity of the blood proteome, spanning a concentration range of at least 10 orders of magnitude [12, 13], we were mainly able to detect blood proteins that change in lung cancer patients. However, to identify cancer-related proteins, the analysis of cancer tissues is preferred. It should be underlined that liquid chromatography mass spectrometry (LC-MS)-based proteomics is being introduced to cancer research as well and now is extensively used for large-scale protein analysis [14–26].

Several studies utilizing the 2D-DIGE approach for the identification of potential lung cancer biomarkers have been published to date, leading to the identification of several potential protein markers [21, 27–30]. The results of these studies have identified numerous protein characteristics for particular cancer types and their progression [10]. However, the biomarkers often differ among studies, which makes it difficult to recommend them as diagnostic targets. It is not surprising due to tumor heterogeneity and difference in analytical procedures used. Therefore the meta-analysis of such data is invaluable. To our knowledge, the majority of these studies have focused on comparing cancer tissue with adjacent normal tissue. Such an approach presents limitations due to intratumoral heterogeneity, which can result in
differences when identifying biomarkers are based on the results of single biopsies [31–33]. It is especially important from the point of view of the occurrence of specific biochemical characteristics at the invasive front of lung cancer [34–36]. Therefore, comparative studies of the center and margin of the tumor could provide important insights into tumor characteristics and development.

In our study, using the 2D-DIGE approach, we sought to compare the proteomes of the tumor center and margin (representing tumor progression) of NSCLC. We hypothesized that these two tumor areas would differ in their proteomic profiles, reflecting different metabolic and structural characteristics. We performed our studies on two subtypes of NSCLC, ADC and SCC. For both subtypes, the proteomes of the tumor center and margin were also compared to the proteome of adjacent normal lung tissues.

**Results**

**2D-DIGE analysis of differentially expressed proteins between center and margin of ADC tumor**

We found 22 differentially abundant spots representing 17 proteins (Fig 1A and 1B and S1 Table). The tumor center was characterized by a higher abundance of LMNA (two proteoforms), dihydropyrimidinase-related protein (DPYSL3), tubulin beta (TUBB), myosin light chain 3 (MYL3), and galectin-1 (LGALS1). On the other hand, the tumor margin was characterized by a higher abundance of moesin isoform X1 (MSN), plastin (LCP1 (three proteoforms), leukotriene A4 hydrolase (LTA4H), mitochondrial heat shock protein 60 kDa (HSPD1), T-complex protein 1, isoform 2 (CCT2), mitochondrial aldehyde dehydrogenase 2 (ALDH2, two proteoforms), tryptophan-tRNA ligase (WARS1), sorting nexin-6 (SNX6), citrate synthase (CS), albumin (ALB), and proteasome alpha 2 subunit (PSMA1). Two proteoforms of carbonic anhydrase 1 (CA1) showed changes in the opposite direction: spot 1828 increased in abundance in the tumor center, while spot 1961 increased in the margin.

![Fig 1. Representative 2D-DIGE profiling of differentially expressed proteins in the margin and center of ADC tumor.](https://doi.org/10.1371/journal.pone.0268073.g001)
2D-DIGE analysis of differentially expressed proteins between center and margin of SCC tumor

We found 21 differentially expressed abundant spots representing 21 proteins (Fig 2A and 2B and S2 Table). The tumor center was characterized by a higher abundance of transferrin (TF), endoplasmic reticulum oxidoreductase 1 (ERO1)-like protein (ERO1A), EH domain-containing protein 1 (EHD1), keratin 5 (KRT5), serpin H1 protein (SERPINH1), and lactate dehydrogenase A (LDHA). On the other hand, the tumor margin was characterized by a higher abundance of TATA binding protein (RUVBL1), PKM isoform d, HNRPF protein (HNRPF), KRT19, serpin B1 protein (SERPINB1), inorganic pyrophosphatase (PPA1), N-acetyl-D-glucosamine kinase isoform 1 (NAGK), F-actin-capping protein (CAPZA1), alpha SNAP (NAPA), microtubule-associated protein RP/EB (MAPRE1), cathepsin D (CTSD), peroxiredoxin 4 (PRDX4), cyclophilin B (PPIB, two proteoforms), and ARHGDIB.

2D-DIGE analysis of differentially expressed proteins between center and margin of ADC tumor compared to control tissue

We found 79 differentially abundant spots representing 68 proteins; 40, 20, and 19 spots differed between the control and center and margin, control and center, and control and margin, respectively (S1 Table). Six proteins (LMNA, LCP1, HSPD1, CS, CA1, and ALB) were previously identified as differentially expressed between the tumor center and margin (S1 Table).

2D-DIGE analysis of differentially expressed proteins between center and margin of SCC tumor compared to control tissue

We found 111 differentially expressed protein spots representing 95 proteins; 84, 7, and 20 spots differed between the control and center and margin, control and center, and control and margin, respectively (S2 Table). Nine proteins (ERO1A, SERPINH1, NAGK, MAPRE1, PPA1, CTSD, LDHA, PRDX4, and PPIB) were previously identified as differentially expressed between the tumor center and margin (S2 Table).

Fig 2. Representative 2D-DIGE profiling of differentially expressed proteins in the margin and center of SCC tumor. (A) single-channel image of proteins from tumor margin, (B) single-channel image of proteins from tumor center. Red numbers indicate proteins that are more abundant in center and green numbers indicate proteins with more abundance in margin. Twenty-one spots for SCC (numbers correlate with descriptions in S2 Table) with significantly different abundance between the margin and center of tumor are shown (p < 0.05).

https://doi.org/10.1371/journal.pone.0268073.g002
Verifying 2D-DIGE results by Western blotting

To verify the 2D-DIGE results, six proteins differing in abundance between the margin and center of ADC (ALDH2, LCP1, and LMNA) and SCC (PKM, KRT19, and ARHGDIB) were selected for further analysis using 1D Western blotting (6 biological replicates in each group). As presented in Fig 3, the changes in the abundance of the selected proteins were consistent with those obtained in the 2D-DIGE analysis. In ADC, the abundance of ALDH2 and LCP1 increased in the margin by 1.4- and 1.2-fold, respectively, while LMNA 80 kDa increased in the center by 1.6-fold (Fig 3A–3C). In SCC, the protein level of PKM and KRT19 increased in the margin by 1.8- and 1.4-fold, respectively, while ARHGDIB increased in the center by 1.4-fold (Fig 3D–3F).

Ingenuity pathway analysis (IPA)

Complete sets of all the IPA results are presented in S1 and S2 Materials.

**Canonical pathways.** ADC. The top five canonical pathways are shown in Table 1. The margin vs. center comparison was characterized by two Rho signaling pathways, the semaphorin neuronal repulsive signaling pathway, epithelial adherens junction signaling, and phenylethylamine degradation. On the other hand, center vs. control and margin vs. control were characterized by three common pathways, acute phase response signaling, glycolysis I, and iron homeostasis signaling pathways. Moreover, the center vs. control comparison was distinguished by phagosome maturation and the remodeling of epithelial adherens junctions, and the margin vs. control comparison was distinguished by aldosterone signaling in epithelial cells and glucocorticoid receptor signaling.

SCC. The top five canonical pathways are shown in Table 2. The margin vs. center was characterized by hypoxia-inducible factor-1α (HIF-1α) signaling, thyroid hormone biosynthesis, phagosome maturation, pyruvate fermentation to lactate, and N-acetylglucosamine degradation II. On the other hand, center vs. control and margin vs. control were characterized by five
common pathways: glucocorticoid receptor signaling, the unfolded protein response, aldosterone signaling in epithelial cells, glycolysis I, and gluconeogenesis I.

Table 1. Top canonical pathways of differentially expressed proteins (DEPs) in ADC tumor.

| Top Canonical Pathways                                   | p-value   | No of molecules | Proteins                                      |
|---------------------------------------------------------|-----------|-----------------|-----------------------------------------------|
| DEPs between Center and Margin                          |           |                 |                                               |
| RhoA Signaling                                          | 3.35E-03  | 2               | MSN, MYL3                                     |
| Semaphorin Neuronal Repulsive Signaling Pathway         | 3.73E-03  | 2               | DPSYL3, MYL3                                  |
| Epithelial Adhers Junction Signaling                    | 5.03E-03  | 2               | MYL3, TUBB                                    |
| RhoGDI Signaling                                        | 7.25E-03  | 2               | MSN, MYL3                                     |
| Phenylethylamine Degradation I                          | 7.62E-03  | 1               | ALDH2                                         |

DEPs between Center and Control

| Acute Phase Response Signaling                          | 2.25E-05  | 5               | ALB, APOA1, HNRNPK, HP, SERPINA1               |
| Glycolysis I                                            | 6.78E-05  | 3               | ENO1, GAPDH, PKM                               |
| Iron homeostasis signaling pathway                      | 1.91E-04  | 4               | HBA1/HBA2, HBB, HBD, HP                        |
| Phagosome Maturation                                    | 2.21E-04  | 3               | CALR, PRDX2, PRDX5, TUBB                       |
| Remodeling of Epithelial Adherens Junctions             | 2.86E-04  | 3               | ACTB, NME1, TUBB                               |

Figure 1: 2D-DIGE analysis of center, margin, and adjacent non-tumor tissues from non-small-cell lung cancer.

Table 2. Top canonical pathways of differentially expressed proteins (DEPs) in SCC tumor.

| Top Canonical Pathways                                   | p-value   | No of molecules | Proteins                                      |
|---------------------------------------------------------|-----------|-----------------|-----------------------------------------------|
| DEPs between Center and Margin                          |           |                 |                                               |
| HIF1α Signaling                                         | 6.47E-04  | 3               | LDHA, PKM, TF                                 |
| Thyroid Hormone Biosynthesis                            | 5.71E-03  | 1               | CTSD                                          |
| Phagosome Maturation                                    | 7.30E-03  | 2               | CTSD, NAPA                                    |
| Pyruvate Fermentation to Lactate                        | 8.15E-03  | 1               | LDHA                                          |
| N-acetylglucosamine Degradation II                      | 9.77E-03  | 1               | NAGK                                          |

DEPs between Center and Control

| Glucocorticoid Receptor Signaling                       | 3.52E-11  | 12              | ACTB, HSP90AA1, HSP90AB1, HSP90B1, HSPA1A/HSPA1B, HSPA5, HSPA8, KRT10, KRT17, KRT5, KRT6B, KRT8 |
|---------------------------------------------------------|-----------|-----------------|-----------------------------------------------|
| Unfolded protein response                               | 4.97E-09  | 6               | CALR, HSP90B1, HSPA1A/HSPA1B, HSPA5, HSPA8, P4HB |
| Aldosterone Signaling in Epithelial Cells              | 7.90E-09  | 8               | HSP90AA1, HSP90AB1, HSP90B1, HSPA1A/HSPA1B, HSPA5, HSPA8, HSPD1, PDIA3 |
| Glycolysis I                                            | 5.94E-08  | 5               | ALDOA, ENO1, GAPDH, PGAM1, PGK1                |
| Gluconeogenesis I                                       | 1.06E-07  | 5               | ALDOA, ENO1, GAPDH, PGAM1, PGK1                |

DEPs between Margin and Control

| Glucocorticoid Receptor Signaling                       | 1.98E-10  | 12              | ACTB, HSP90AA1, HSP90AB1, HSP90B1, HSPA1A/HSPA1B, HSPA5, HSPA8, KRT10, KRT17, KRT5, KRT6B, KRT8 |
|---------------------------------------------------------|-----------|-----------------|-----------------------------------------------|
| Aldosterone Signaling in Epithelial Cells              | 1.09E-09  | 9               | HSP90AA1, HSP90AB1, HSP90B1, HSPA1A/HSPA1B, HSPA5, HSPA8, HSPB1, HSPD1, PDIA3 |
| Unfolded protein response                               | 1.17E-08  | 6               | CALR, HSP90B1, HSPA1A/HSPA1B, HSPA5, HSPA8, P4HB |
| Glycolysis I                                            | 1.21E-07  | 5               | ALDOA, ENO1, GAPDH, PGAM1, PGK1                |
| Gluconeogenesis I                                       | 2.15E-07  | 5               | ALDOA, ENO1, GAPDH, PGAM1, PGK1                |

https://doi.org/10.1371/journal.pone.0268073.t001

https://doi.org/10.1371/journal.pone.0268073.t002
Disease and disorder categories. ADC. The top five disease and disorder categories are shown in Table 3. The margin vs. center comparison was characterized by immunological, hematological, and inflammatory disease; inflammatory responses and organismal injury and abnormalities were indicated as well. The latter category for all the comparisons comprised

Table 3. Top disease and disorder of differentially expressed proteins (DEPs) in ADC tumor.

| Disease and Disorder         | p-value       | No of molecules | Proteins                                                                 |
|------------------------------|---------------|-----------------|--------------------------------------------------------------------------|
| Immunological Disease        | 1.79E-02–2.15E-06 | 10 ALB, ALDH2, CA1, HSPD1, LCP1, LGALS1, LTA4H, MSN, TUBB, WARS1    |
| Hematological Disease        | 1.59E-02–3.88E-06 | 4 ALB, ALDH2, CA1, TUBB                                         |
| Inflammatory Disease         | 1.79E-02–3.88E-06 | 9 ALB, ALDH2, CA1, HSPD1, LCP1, LGALS1, LTA4H, TUBB, WARS1      |
| Inflammatory Response        | 1.93E-02–3.88E-06 | 10 ALB, ALDH2, CA1, CCT2, HSPD1, LCP1, LGALS1, LTA4H, MSN, TUBB  |
| Organismal Injury and Abnorm   | 1.99E-02–3.88E-06 | 17 ALB, ALDH2, CA1, CCT2, CS, DPYSL3, HSPD1, LCP1, LGALS1, LMNA, LTA4H, MSN, MYL3, PSM1, SNX6, TUBB, WARS1 |

DEPs between Center and Control

Endocrine System Disorders 1.65E-03–4.84E-15 43 AKR1B1, ALB, ANXA2, ANXA3, ANXA4, APOA1, ATIC, CA1, CALR, EEF1A1, EEF1B2, EEF2, ENO1, G6PD, GAPDH, HBA1/HBA2, HBB, HBH, HDGF, HNRRNPK, HP, HSP90AB1, IDH1, ILF2, LCP1, MZB1, PDI4, PFMN, PKM, PPA1, PPA1, PRDX2, PRDX5, PSMD7, RBBP4, RPSA, S100A4, SERPINA1, SN1D, TUBB, UGDH, YWHAZ

Organismal Injury and Abnorm   1.88E-03–4.84E-15 46 ACTB, AKR1B1, ALB, ANXA2, ANXA3, ANXA4, APOA1, ATIC, CA1, CALR, EEF1A1, EEF1G, EEF2, ENO1, G6PD, GAPDH, HBA1/HBA2, HBB, HBH, HDGF, HNRRNPK, HP, HSP90AB1, IDH1, ILF2, LCP1, LPP, MZB1, NME1, PDI4, PFMN, PKM, PPA1, PPA1, PRDX2, PRDX5, PSMD7, RBBP4, RPSA, S100A4, SERPINA1, SN1D, TUBB, UGDH, YWHAZ

Inflammatory Response         1.65E-03–2.95E-13 33 ACTB, ALB, ANXA2, ANXA3, ANXA4, APOA1, ATIC, CA1, CALR, EEF1A1, EEF1B2, EEF2, ENO1, G6PD, GAPDH, HBA1/HBA2, HBB, HBH, HDGF, HNRRNPK, HP, HSP90AB1, IDH1, ILF2, LCP1, MZB1, NME1, PFMN, PKM, PPA1, PRDX2, PRDX5, PSMD7, RBBP4, RPSA, S100A4, SERPINA1, SN1D, TUBB, UGDH, YWHAZ

Immunological Disease        1.88E-03–3.31E-12 36 ACTB, AKR1B1, ALB, ANXA2, ANXA3, ANXA4, APOA1, ATIC, CA1, CALR, EEF1A1, EEF1G, EEF2, ENO1, G6PD, GAPDH, HBA1/HBA2, HBB, HBH, HDGF, HNRRNPK, HP, HSP90AB1, IDH1, ILF2, LCP1, MZB1, NME1, PDMN, PKM, PPA1, PRDX2, PRDX5, PSMD7, RBBP4, RPSA, S100A4, SERPINA1, SN1D, TUBB, UGDH, YWHAZ

Gastrointestinal Disease      1.88E-03–7.04E-12 45 ACTB, AKR1B1, ALB, ANXA2, ANXA3, ANXA4, APOA1, ATIC, CA1, CALR, EEF1A1, EEF1B2, EEF2, ENO1, G6PD, GAPDH, HBA1/HBA2, HBB, HBH, HDGF, HNRRNPK, HP, HSP90AB1, IDH1, IMPDH2, KRT19, KRT34, LMNA, NME1, PDI4, PKM, PPA1, PPA1, PRDX2, PRDX5, PSMD7, RBBP4, RPSA, S100A4, SERPINA1, SN1D, TUBB, UGDH, YWHAZ

DEPs between Margin and Control

Cancer                       1.88E-03–2.44E-14 45 ACTB, AHCY, ALB, ALDH1A1, ANXA3, ATIC, CA1, CS, EEF1A1, EEF1B2, EEF1D, EEF2, ENO1, FGB, GAPDH, HBA1/HBA2, HBB, HBH, HDNRNPK, HP, HSP90AB1, HSPA1A/HSPA1B, HSPD1, IDH1, IMPDH2, KRT19, KRT34, LMNA, NME1, PDI4, PKM, PPA1, PPA1, PRDX2, PRDX5, PSMD7, RBBP4, RPSA, S100A4, SERPINA1, SN1D, TAGLN, TXNRR1D, UGDH, VIM

Gastrointestinal Disease     1.88E-03–2.44E-14 46 ACTB, AHCY, ALB, ALDH1A1, ANXA3, ATIC, CA1, CS, EEF1A1, EEF1B2, EEF1D, EEF2, ENO1, FGB, GAPDH, HBA1/HBA2, HBH, HBH, HDNRNPK, HP, HSP90AB1, HSPA1A/HSPA1B, HSPD1, IDH1, IMPDH2, KRT19, KRT34, LMNA, NME1, PDI4, PKM, PPA1, PPA1, PRDX2, PRDX5, PSMD7, RBBP4, RPSA, S100A4, SERPINA1, SERPINB1, SN1D, TAGLN, TXNRR1D, UGDH, VIM

Hepatic System Disease       1.88E-03–2.44E-14 33 ACTB, ALB, ALDH1A1, ANXA3, ATIC, CS, EEF1A1, EEF2, ENO1, FGB, HBA1/HBA2, HBH, HBH, HDNRNPK, HP, HSP90AB1, HSPA1A/HSPA1B, HSPD1, IDH1, IMPDH2, KRT19, KRT34, LMNA, NME1, PDI4, PKM, PPA1, PPA1, PRDX2, PRDX5, PSMD7, RBBP4, RPSA, S100A4, SERPINA1, SERPINB1, SN1D, TAGLN, TXNRR1D, UGDH, VIM

Organismal Injury and Abnorm  1.88E-03–2.44E-14 46 ACTB, AHCY, ALB, ALDH1A1, ANXA3, ATIC, CA1, CS, EEF1A1, EEF1B2, EEF1D, EEF2, ENO1, FGB, GAPDH, HBA1/HBA2, HBH, HBH, HDNRNPK, HP, HSP90AB1, HSPA1A/HSPA1B, HSPD1, IDH1, IMPDH2, KRT19, KRT34, LMNA, MZB1, NME1, PDI4, PKM, PPA1, PPA1, PRDX2, PRDX5, PSMD7, RBBP4, RPSA, S100A4, SERPINA1, SERPINB1, SN1D, TAGLN, TXNRR1D, UGDH, VIM

Inflammatory Response        1.56E-03–2.95E-13 30 ACTB, AHCY, ALB, ANXA3, ATIC, CA1, EEF1A1, EEF2, ENO1, FGB, GAPDH, HBA1/HBA2, HBH, HBH, HSP90AB1, HSPA1A/HSPA1B, HSPD1, IDH1, IMPDH2, MZB1, PKM, PPA1, PPA1, PRDX5, PSMD7, RPSA, S100A4, SERPINA1, SERPINB1, SN1D, TAGLN, TXNRR1D, UGDH, VIM

https://doi.org/10.1371/journal.pone.0268073.t003
several cancers, including lung cancer annotations (for details, see S1 Material). On the other hand, center vs. control and margin vs. control were characterized by the same three categories: organismal injury and abnormalities, gastrointestinal disease, and inflammatory responses. Additionally, the categories endocrine system disorders and immunological disease were indicated for center vs. control and cancer and hepatic system disease for margin vs. control comparison.

**SCC.** The top five disease and disorder categories are shown in Table 4. Similar to ADC, the margin vs. center comparison was characterized by inflammatory responses and organismal injury and abnormalities; connective tissue, developmental, and hereditary disorders were indicated as well. On the other hand, center vs. control and margin vs. control were characterized by the same categories, hematomal disease and organismal injury and abnormalities, comprising several cancers, including lung cancer annotations (for details, see S2 Material). Cancer was also indicated in the center vs. control comparison, together with gastrointestinal and hepatic system disease, whereas margin vs. control was characterized by immunological and inflammatory disease and inflammatory response.

**Molecular and cellular functions.** ADC. The top five molecular and cellular functions categories are shown in Table 5. The margin vs. center comparison was characterized by cellular movement, cell morphology, cell death and survival, cellular development, and lipid metabolism. On the other hand, center vs. control and margin vs. control were characterized by the same four categories: cellular compromise, cellular movement, cell death and survival, and free radical scavenging. Cellular development was also indicated in the center vs. control comparison, and small molecule biochemistry, in margin vs. control.

**SCC.** The top five molecular and cellular function categories are shown in Table 6. The margin vs. center comparison was characterized by post-translational modification, protein folding, cellular development, cellular growth and proliferation, and cellular assembly and organization. On the other hand, center vs. control and margin vs. control were characterized by the same four categories: cellular movement, cell death and survival, cellular compromise, and post-translational modification. Cellular function and maintenance were also indicated in the center vs. control comparison, and protein folding, in margin vs. control.

**Upstream regulator.** ADC. The upstream regulators are shown in S1 Material. In the center vs. margin comparison L-triiodothyronine (p = 3.31E-04; z score -2.000) was marked as significantly inhibited regulator. In the center vs. control comparison La-related protein 1 (LARP1; p = 2.09E-05; z-score -2.000); IND S1 (p = 9.09E-08; z-score -2.000); IND S7 (p = 2.52E-07; z-score -2.000) and MEL S3 (p = 2.92E-07; z-score -2.000) were marked as inhibited regulators whereas interleukin-15 (IL15; p = 2.40E-05; z-score 2.000); prostate cancer gene expression marker 1 (PCGEM1; p = 1.83E-08; z-score 2.201); lysine demethylase 8 (KDM8; p = 3.32E-07 z-score 2.219); testosterone (p = 9.11E-04; z-score 2.236) and nuclear factor erythroid 2-related factor 2 (NFE2L2; p = 2.42E-04; z-score 2.391) were activated regulators. In the margin vs. control comparison 5-fluorouracil (p = 5.79E-04; z-score -2.000); caseinolytic protease P (CLPP; p = 7.91E-06; z-score -2.000) were inhibited regulators, whereas NFE2L2 (p = 2.47E-06; z-score 2.184); PCGEM1 (p = 1.83E-08; z-score 2.207); N-myc proto-oncogene protein (MYCN; p = 7.11E-15; z-score 2.382), serine/threonine kinase 11 (STK11; p = 2.73E-10; z-score 2.530) and Myc proto-oncogene protein (MYC; p = 8.90E-10; z-score 2.789) were activated regulators.

**SCC.** The upstream regulators are shown in S2 Material. No upstream regulators were identified in the center vs. margin comparison. In the center vs. control comparison sirolimus (p = 3.20E-13; z-score -3.492); CD 437 (p = 1.41E-13; z-score 3.464); ST1926 (p = 3.19E-13; z-score -3.317); tretinoin (p = 2.19E-04; z-score -2.885) and CLPP (p = 3.02E-10; z-score -2.646) were marked as inhibited regulators, whereas 6-hydroxydopamine (6-OHDA; p = 7.79E-12; z-
Table 4. Top disease and disorder of differentially expressed proteins (DEPs) in SCC tumor.

| Disease and Disorder                  | p-value          | No of molecules | Proteins                                                                 |
|---------------------------------------|------------------|-----------------|--------------------------------------------------------------------------|
| **DEPs between Center and Margin**    |                  |                 |                                                                          |
| Inflammatory Response                 | 4.92E-02–6.94E-06| 13              | ARHGDB, CTSD, EHDI, KRT5, NAGK, NAP, PKM, PPB, PRDX4, RUVBL1, SERPINB1, SERPINH1, TF |
| Organismal Injury and Abnormalities   | 4.95E-02–6.94E-06| 20              | ARHGDB, CAPZA1, CTSD, EHDI, ERO1A, HNRRNP6, KRT19, KRT5, LDHA, MAPRE1, NAGK, NAP, PKM, PPB, PRDX4, RUVBL1, SERPINB1, SERPINH1, TF |
| Connective Tissue Disorders           | 4.26E-02–4.93E-05| 5               | KRT5, MAPRE1, PPB, SERPINH1, TF                                          |
| Developmental Disorder                | 4.79E-02–4.93E-05| 8               | ARHGDB, CTSD, EHDI, KRT5, LDHA, PPB, SERPINH1, TF                        |
| Hereditary Disorder                   | 4.79E-02–4.93E-05| 9               | ARHGDB, CTSD, KRT5, NAP, PKM, PPB, SERPINH1, TF                        |
| **DEPs between Center and Control**   |                  |                 |                                                                          |
| Cancer                                | 1.11E-05–1.19E-19| 58              | ACO2, ACTB, ALB, ALDOA, CA1, CA2, CALR, CFL1, CLIC1, CS, CSTD, EF1A1, EEF2, EEF4A2, ERO1A, ESR, GAPDH, GSTP1, HB1A1/HB2A, HBB, HB, HNRRPH1, HNRRNPK, HSP90A1A, HSP90A1B, HSP90B1, HSPA1A/HSPA1B, HSPA5, HSPA8, HSPD1, IDH1, KRT10, KRT17, KRT5, KRT6B, KRT8, LDHA, MAPRE1, NME1, P4HB, PDI3, PDI4, PGAM1, PGK1, RACK1, RPSA, S100A11, SERPINB1, SERPINH1, SFN, SOD2, TPSAB1/TPSB2, TUBA1B, VDAC1, YWHA, YWHA, YWHAZ |
| Gastrointestinal Disease             | 9.30E-06–1.19E-19| 55              | ACO2, ACTB, ALB, ALDOA, CA1, CA2, CALR, CFL1, CLIC1, CS, CSTD, EF1A1, EEF2, EEF4A2, ERO1A, ESR, GAPDH, GSTP1, HB1A1/HB2A, HBB, HB, HNRRPH1, HNRRNPK, HSP90A1A, HSP90A1B, HSP90B1, HSPA5, HSPA8, HSPD1, IDH1, KRT10, KRT17, KRT5, KRT6B, KRT8, LDHA, MAPRE1, NME1, P4HB, PDI3, PDI4, PGAM1, PGK1, RACK1, RPSA, S100A11, SERPINB1, SERPINH1, SFN, SOD2, TPSAB1/TPSB2, VDAC1, YWHA, YWHA, YWHAZ |
| Hepatic System Disease                | 8.58E-06–1.19E-19| 38              | ACO2, ACTB, ALB, ALD0A, CA1, CA2, CALR, CFL1, CLIC1, CS, CSTD, EF1A1, EEF2, EEF4A2, ERO1A, ESR, GAPDH, GSTP1, HB1A1/HB2A, HBB, HB, HNRRPH1, HNRRNPK, HSP90A1A, HSP90A1B, HSP90B1, HSPA5, HSPA8, HSPD1, IDH1, KRT10, KRT8, LDHA, MAPRE1, NME1, P4HB, PDI3, PDI4, PGK1, RACK1, RPSA, S100A11, SERPINB1, SERPINH1, SFN, SOD2, TPSAB1/TPSB2, VDAC1, YWHA, YWHA, YWHAZ |
| Organismal Injury and Abnormalities   | 1.11E-05–1.19E-19| 59              | ACO2, ACTB, ALB, ALDOA, CA1, CA2, CALR, CFL1, CLIC1, CS, CSTD, EF1A1, EEF2, EEF4A2, ERO1A, ESR, GAPDH, GSTP1, HB1A1/HB2A, HBB, HB, HNRRPH1, HNRRNPK, HSP90A1A, HSP90A1B, HSP90B1, HSPA5, HSPA8, HSPD1, IDH1, KRT10, KRT8, LDHA, MAPRE1, NME1, P4HB, PDI3, PDI4, PGK1, RACK1, RPSA, S100A11, SERPINB1, SERPINH1, SFN, SOD2, TPSAB1/TPSB2, VDAC1, YWHA, YWHA, YWHAZ |
| Hematological Disease                 | 9.30E-06–1.07E-17| 40              | ACO2, ACTB, ALB, ALDOA, CA1, CA2, CALR, CFL1, EF1A1, ENO1, GAPDH, GSTP1, HB1A1/HB2A, HBB, HB, HNRRPH1, HNRRNPK, HSP90A1A, HSP90A1B, HSP90B1, HSP90B2, HSPA1A/HSPA1B, HSPA5, HSPA8, HSPD1, IDH1, KRT10, KRT7, KRT5, KRT6B, KRT8, LDHA, MAPRE1, NME1, P4HB, PDI3, PDI4, PGAM1, PGK1, RACK1, RPSA, S100A11, SERPINB1, SERPINH1, SFN, SOD2, TPSAB1/TPSB2, TUBA1B, VDAC1, YWHA, YWHA, YWHAZ |
| **DEPs between Margin and Control**   |                  |                 |                                                                          |
| Hematological Disease                 | 9.35E-06–3.66E-19| 44              | ACO2, ACTB, ALB, ALDOA, CA1, CA2, CALR, CFL1, EF1A1, ENO1, G6PD, GAPDH, GSTP1, HB1A1/HB2A, HBB, HSP90A1A, HSP90A1B, HSP90B1, HSP90B2, HSPA1A/HSPA1B, HSPA5, HSPA8, HSPD1, IDH1, KRT10, KRT7, KRT5, LDHA, MAPRE1, MYH9, NME1, P4HB, PDI3, PGK1, PPIA, PRDX4, RACK1, RPSA, S100A11, S100A9, SERPINB1, SFN, SOD2, TUBA1B, VDAC1, YWHA, YWHA, YWHAZ |
| Immunological Disease                 | 9.35E-06–3.66E-19| 50              | ACO2, ACTB, ALB, ALDOA, APOA1, CA1, CA2, CALR, CFL1, EF1A1, EF1G, EF2, ENO1, G6PD, GAPDH, GSTP1, HB1A1/HB2A, HBB, HSP90A1A, HSP90B1, HSP90B2, HSPA1A/HSPA1B, HSPA5, HSPA8, HSPD1, IDH1, KRT10, KRT7, KRT5, LDHA, MAPRE1, MYH9, NAGK, NME1, P4HB, PDI3, PGK1, PPIA, PRDX4, RACK1, RPSA, S100A11, S100A9, SERPINB1, SFN, SOD2, TUBA1B, VDAC1, YWHA, YWHA, YWHAZ |
| Inflammatory Disease                  | 7.46E-06–3.66E-19| 42              | ACO2, ACTB, AACTR3, ALB, ALDOA, APOA1, CA1, CA2, CALR, CCT8, CFL1, EF1A1, EF1G, EF2, ENO1, G6PD, GAPDH, GSTP1, HB1A1/HB2A, HBB, HSP90A1A, HSP90A1B, HSP90B1, HSP90B2, HSPA1A/HSPA1B, HSPA5, HSPA8, HSPD1, IDH1, KRT10, KRT7, KRT5, KRT8, MAPRE1, MYH9, NAGK, P4HB, PDI3, PGAM1, PGK1, PPIA, PRDX4, RACK1, RPSA, S100A11, S100A9, SERPINB1, SFN, SOD2, TTR |
| Inflammatory Response                 | 7.46E-06–3.66E-19| 47              | ACO2, ACTB, ALB, ALDOA, APOA1, CA1, CA2, CALR, CCT8, CFL1, EF1A1, EF1G, EF2, ENO1, G6PD, GAPDH, GSTP1, HB1A1/HB2A, HBB, HSP90A1A, HSP90A1B, HSP90B1, HSP90B2, HSPA1A/HSPA1B, HSPA5, HSPA8, HSPD1, IDH1, KRT10, KRT7, KRT5, KRT8, MAPRE1, MYH9, NAGK, P4HB, PDIAM, PGAM1, PGK1, PPIA, PRDX4, RACK1, RPSA, S100A11, S100A9, SERPINB1, SFN, SOD2, TTR |
Table 4. (Continued)

| Disease and Disorder                          | p-value          | No of molecules | Proteins                                      |
|-----------------------------------------------|------------------|-----------------|-----------------------------------------------|
| Organisinal Injury and Abnormalities          | 1.17E-05–3.66E-19| 69              | ACO2, ACTB, ACTR3, ALB, ALDOA, APOA1, CA1, CA2, CALR, CCT8, CFL1, CLIC1, CS, EEF1A1, EEF1G, EEF2, EIF4A2, ENO1, EZR, G6PD, GAPDH, GSTP1, HBA1/HBA2, HBB, HBD, HNRNPH1, HNRNPK, HSP90AA1, HSP90AB1, HSP90B1, HSPA1A/HSPA1B, HSPA5, HSPA8, HSPD1, IDH1, KRT10, KRT17, KRT5, KRT6B, KRT8, LDHA, MAPRE1, MYH9, MYL6, NAGK, NME1, P4HB, PDI3, PDIA4, PGAM1, PGK1, PPA1, PPIA, PPIB, PRDX4, RACK1, RPSA, S100A11, S100A9, SELENBP1, SFN, SOD2, TTR, TUBA1B, VDAC1, YWHAB, YWHAE, YWHAZ |

score 2.985); NFE2L2 (p = 9.75E-11; z-score 3.050); beta-estradiol (p = 5.74E-20; z-score 3.229); lipopolysaccharide (p = 2.97E-06; z-score 3.379) and insulin (p = 2.99E-12; z-score 3.229).

Table 5. Molecular and cellular functions of differentially expressed proteins (DEPs) in ADC tumor.

| Molecular and Cellular Functions | p-value          | No of molecules | Proteins                                      |
|---------------------------------|------------------|-----------------|-----------------------------------------------|
| Cellular Movement              | 2.00E-02–3.88E-06| 10              | ALB, ALDH2, DPYS3, HSPD1, LCP1, LGALS1, LMNA, MSN, TUBB, WARS1 |
| Cell Morphology                 | 2.02E-02–2.99E-05| 8               | ALB, DPYS3, HSPD1, LCP1, LGALS1, LMNA, MSN, MYL3 |
| Cell Death and Survival         | 1.95E-02–4.80E-05| 12              | ALB, ALDH2, CCT2, CS, DPYS3, HSPD1, LCP1, LGALS1, LMNA, MSN, SNX6, TUBB |
| Cellular Development            | 1.88E-02–1.81E-04| 7               | ALB, DPYS3, HSPD1, LCP1, LGALS1, LMNA, MSN |
| Lipid Metabolism                | 1.86E-02–1.82E-04| 6               | ALB, CS, LGALS1, LMNA, LTA4H, MSN |

DEPs between Center and Margin

| Cellular Compromise             | 1.44E-12–2.95E-13| 16              | ALB, ANXA2, ANXA3, APOA1, EEF1A1, EEF2, HBB, HP, HSP90AB1, IDH1, IIF2, PKM, PPIA, PSMD7, SERPINA1, TUBB |
| Cell Death and Survival         | 1.88E-03–1.16E-12| 35              | ACTB, AKR1B1, ALB, ANxa2, ANxa3, APOA1, ATIC, CALR, EEF1A1, EEF2, ENO1, G6PD, GAPDH, HBA1/HBA2, HBB, HDGF, HNRNPK, HSP90AB1, IDH1, IIF2, MZB1, NME1, PFI1, PKM, PPIA, PRDX2, PRDX5, PSMD7, RBBP4, RPSA, S100A4, SERPINA1, SND1, TUBB, YWHAZ |
| Free Radical Scavenging         | 1.76E-03–1.41E-12| 18              | ACTB, AKR1B1, ALB, ANXA2, APOA1, G6PD, HBA1/HBA2, HBB, HNRNPK, HP, HSP90AB1, IDH1, PFN1, PPIA, PRDX2, PRDX5, SERPINA1, YWHAZ |
| Cellular Movement               | 1.76E-03–2.52E-12| 29              | ACTB, AKR1B1, ALB, ANXA2, APOA1, CALR, ENO1, G6PD, GAPDH, HDGF, HNRNPK, HP, HSP90AB1, IDH1, LCP1, LLP, NME1, PFI1, PKM, PPIA, PRDX2, RPSA, S100A4, SERPINA1, SND1, TUBB, UGDH, YWHAZ |
| Cellular Development            | 1.87E-03–2.93E-08| 25              | ACTB, AKR1B1, ANXA2, APOA1, CALR, EEF1A1, EEF1B2, G6PD, GAPDH, HDGF, HNRNPK, ILF2, LCP1, NME1, PFN1, PKM, PPIA, PRDX2, RPSA, S100A4, SERPINA1, SND1, TUBB, UGDH, YWHAZ |

DEPs between Margin and Control

| Cellular Compromise             | 1.88E-03–2.95E-13| 17              | ALB, ANXA3, EEF1A1, EEF2, FGB, HBB, HP, HSP90AB1, HSP9A1A/HSP9A1B, IDH1, IMPDH2, PKM, PPIA, PSMD7, S100A4, SERPINA1, SERPINB1 |
| Cell Death and Survival         | 1.88E-03–5.12E-10| 34              | ACTB, ALB, ALDH1A1, ATIC, CS, EEF1A1, EEF1D, EEF2, ENO1, GAPDH, HBA1/HBA2, HBB, HNRNPK, HSP90AB1, HSPA1A/HSPA1B, HSPD1, IDH1, IMPDH2, KRT19, LMNA, MZB1, NME1, PKM, PPIA, PRDX5, PSMD7, RBBP4, RPSA, S100A4, SERPINA1, SERPINB1, SND1, TXNRD1, VIM |
| Cellular Movement               | 1.56E-03–1.05E-09| 27              | ACTB, AHY, ALB, ANXA3, ENO1, FGB, GAPDH, HNRNPK, HP, HSP90AB1, HSPA1A/HSPA1B, HSPD1, IDH1, KRT19, LMNA, NME1, PKM, PPIA, RPSA, S100A4, SERPINA1, SERPINB1, SND1, TAGLN, TXNRD1, UGDH, YIM |
| Free Radical Scavenging         | 7.50E-04–2.62E-08| 13              | ACTB, HBA1/HBA2, HBB, HNRNPK, HP, HSP90AB1, IDH1, PPIA, PRDX5, SERPINA1, TAGLN, TXNRD1 |
| Small Molecule Biochemistry     | 1.88E-03–1.86E-07| 26              | AHY, ALB, ALDH1A1, CS, EEF1A1, EF1B2, ENO1, GAPDH, HBA1/HBA2, HBB, HSP90AB1, HSPA1A/HSPA1B, HSPD1, IDH1, IMPDH2, LMNA, MZB1, NME1, PKM, PPIA, PRDX5, RPSA, SERPINA1, TXNRD1, UGDH, VIM |
3.411) were activated regulators. In the margin vs. control comparison sirolimus (p = 2.30E-14; z-score -3.758); CD 437 (p = 8.31E-13; z-score -3.464); ST1926 (p = 1.61E-12; z-score -3.317); tretinoin (p = 7.08E-05; z-score -3.053); CLPP (p = 8.27E-10; z-score -2.646) were inhibited regulators, whereas 1.2-dithiol-3-thione (p = 2.41E-11; z-score 3.289); lipopolysaccharide (p = 7.25E-08; z-score 3.318); insulin (p = 8.67E-15; z-score 3.3570); NFE2L2 (p = 4.74E-11; z-score 3.653) and MYC (p = 5.26E-13; z-score 3.684) were activated regulators.

Table 6. Molecular and cellular functions of differentially expressed proteins (DEPs) in SCC tumor.

| Molecular and Cellular Functions | p-value | No of molecules | Proteins |
|---------------------------------|---------|----------------|----------|
| DEPs between Center and Margin  |         |                |          |
| Post-Translational Modification | 3.62E-02–1.77E-05 | 6 | CAPZA1, CTSD, ERO1A, PRDX4, RUVB1, TF |
| Protein Folding                 | 1.77E-05–1.77E-05 | 2 | ERO1A, PRDX4 |
| Cellular Development            | 4.95E-02–2.36E-05 | 12 | ARHGDI1, CTSD, EHD1, ERO1A, KRT19, LDHA, MAPRE1, PKM, PRDX4, RUVB1, SERPINH1, TF |
| Cellular Growth and Proliferation| 4.95E-02–2.36E-05 | 12 | ARHGDI1, CTSD, EHD1, ERO1A, KRT19, LDHA, MAPRE1, PKM, PRDX4, RUVB1, SERPINH1, TF |
| Cellular Assembly and Organization| 4.40E-02–8.84E-05 | 9 | CTSD, EHD1, KRT19, MAPRE1, NAPA, PKM, PPIB, SERPINH1, TF |
| DEPs between Center and Control |         |                |          |
| Cellular Movement               | 9.72E-06–9.28E-18 | 42 | ACO2, ACTB, ALB, ALDOA, CA2, CALR, CFL1, CLIC1, CTSD, ENO1, EZR, GAPDH, HNRNPK, HSP90AA1, HSP90AB1, HSP90B1, HSPA1A/HSPA1B, HSPAP5, HSPAP8, HSPAPD1, IDH1, KRT10, KRT17, KRT6B, KRT8, LDHA, MAPRE1, NME1, P4HB, PIA3, PPIB, RACK1, RPSA, S100A11, SERPINB1, SERPINH1, SFN, SOD2, TPASB1/TPSB2, VDAC1, YWHAE, YWHAZ |
| Cell Death and Survival         | 7.54E-06–7.88E-16 | 47 | ACO2, ACTB, ALB, ALDOA, CA2, CALR, CFL1, CS, CTSD, EEI1A1, EEI2, ERO1A, EZR, GAPDH, GSTP1, HBA1/HBA2, HBB, HNRNPH1, HNRNPK, HSP90AA1, HSP90AB1, HSP90B1, HSPA1A/HSPA1B, HSPA5, HSPA8, HSPAPD1, IDH1, KRT10, KRT17, KRT6B, KRT8, LDHA, MAPRE1, NME1, P4HB, PIA3, PPIB, RACK1, RPSA, S100A11, SERPINB1, SERPINH1, SFN, SOD2, TPASB1/TPSB2, VDAC1, YWHAB, YWHAE, YWHAZ |
| Cellular Compromise             | 5.99E-06–1.51E-11 | 21 | ALB, ALDOA, CALR, CTSD, EEI1A1, EEI2, ERO1A, GSTP1, HBB, HSP90AA1, HSP90AB1, HSP90B1, HSPA1A/HSPA1B, HSPA5, HSPA8, HSPAPD1, IDH1, P4HB, PGM1, S100A11, SERPINH1 |
| Cellular Function and Maintenance| 7.35E-06–1.51E-11 | 36 | ACTB, ALB, ALDOA, CA2, CALR, CFL1, CLIC1, CTSD, EEDF1A1, EEI2, ERO1A, EZR, GAPDH, GSTP1, HBA1/HBA2, HBB, HNRNPK, HSP90AA1, HSP90AB1, HSP90B1, HSPA1A/HSPA1B, HSPA5, HSPA8, HSPAPD1, IDH1, KRT17, KRT6B, KRT8, LDHA, MAPRE1, NME1, P4HB, PIA3, PPIA, PPIB, RACK1, RPSA, S100A11, SERPINB1, SERPINH1, SFN, SOD2, TPRAB1/TPRB2, VDAC1, YWHAE, YWHAZ |
| Post-Translational Modification | 3.35E-07–4.22E-11 | 9 | CALR, ERO1A, HSP90AA1, HSP90AB1, HSPA1A/HSPA1B, HSPA5, HSPA8, HSPAPD1, PIA3 |
| DEPs between Margin and Control |         |                |          |
| Cellular Movement               | 1.23E-06–3.24E-20 | 47 | ACO2, ACTB, ACTR3, ALB, ALDOA, APOA1, CA2, CALR, CFL1, CLIC1, ERO1A, EZR, G6PD, GAPDH, HNRNPK, HSP90AA1, HSP90AB1, HSP90B1, HSPA1A/HSPA1B, HSPA5, HSPA8, HSPAPD1, IDH1, KRT10, KRT17, KRT6B, KRT8, LDHA, MAPRE1, MYH9, NME1, P4HB, PIA3, PPIA, PPIB, RACK1, RPSA, S100A11, S100A9, SERPINB1, SFN, SOD2, TTR, VDAC1, YWHAE, YWHAZ |
| Cell Death and Survival         | 8.81E-06–3.51E-16 | 52 | ACO2, ACTB, ALB, ALDOA, APOA1, CA2, CALR, CCT8, CFL1, CS, EEI1A1, EEI2, ERO1A, EZR, G6PD, GAPDH, GSTP1, HBA1/HBA2, HBB, HNRNPK, HSP90AA1, HSP90AB1, HSP90B1, HSPA1A/HSPA1B, HSPA5, HSPA8, HSPAPD1, IDH1, KRT10, KRT17, KRT6B, KRT8, LDHA, MAPRE1, NME1, P4HB, PIA3, PPIA, PPIB, RACK1, RPSA, S100A11, S100A9, SERPINB1, SFN, SOD2, TTR, VDAC1, YWHA, YWHAZ |
| Post-Translational Modification | 5.90E-07–3.26E-15 | 12 | CALR, CCT8, HSP90AA1, HSP90AB1, HSPA1A/HSPA1B, HSPA5, HSPA8, HSPAPD1, PIA3, PPIA, PRDX4 |
| Protein Folding                 | 5.90E-07–3.26E-15 | 12 | CALR, CCT8, HSP90AA1, HSP90AB1, HSPA1A/HSPA1B, HSPA5, HSPA8, HSPAPD1, PIA3, PPIA, PRDX4 |
| Cellular Compromise             | 2.54E-06–4.06E-14 | 24 | ALB, ALDOA, APOA1, CALR, CCT8, EEI1A1, EEI2, GSTP1, HBB, HSP90AA1, HSP90AB1, HSP90B1, HSPA1A/HSPA1B, HSPA5, HSPA8, HSPAPD1, IDH1, P4HB, PGM1, PPIA, PRDX4, S100A11, S100A9, TTR |

https://doi.org/10.1371/journal.pone.0268073.t006
STRING analysis

Complete sets of all the STRING results are presented in S3–S8 Materials.

ADC. The margin vs. center comparison indicated 19 significant interactions specified by GO analysis. Fig 4A highlights interactions related to the interleukin-12-mediated signaling pathway, leukocyte activation, and the positive regulation of podosome assembly. The center vs. control comparison indicated 158 significant interactions specified by GO analysis. Fig 4B highlights interactions related to leukocyte activation involved in the immune response and vesicle-mediated transport. The margin vs. control comparison indicated 139 significant interactions specified by GO analysis. Fig 4C highlights interactions related to regulated exocytosis and leukocyte activation involved in the immune response.

SCC. The margin vs. center comparison indicated four significant interactions specified by GO analysis. Fig 5A highlights interactions related to the 4-hydroxyproline metabolic process, protein maturation by protein folding, vesicle-mediated transport, pyruvate metabolism, glycolysis/gluconeogenesis, the carboxylic acid metabolic process, and vesicle-mediated transport. The center vs. control comparison indicated 365 significant interactions specified by GO analysis. Fig 5B highlights interactions related to the regulation of cell death, glycolysis, and response to stress. The margin vs. control comparison indicated 373 significant interactions specified by GO analysis. Fig 5C highlights interactions related to protein folding and vesicle-mediated transport.

IPA networks

ADC. For the margin vs. center comparison, IPA indicated two networks: (i) cellular movement, hematological disease, and immunological disease, consisting of 10 proteins, and (ii) cell death and survival, cellular movement, and organismal injury and abnormalities, consisting of seven proteins. The cellular movement, hematological disease, immunological disease network is shown in Fig 6A, overlaid with signaling by the Rho GTPase canonical pathway.

IPA networks

ADC. For the margin vs. center comparison, IPA indicated two networks: (i) cellular movement, hematological disease, and immunological disease, consisting of 10 proteins, and (ii) cell death and survival, cellular movement, and organismal injury and abnormalities, consisting of seven proteins. The cellular movement, hematological disease, immunological disease network is shown in Fig 6A, overlaid with signaling by the Rho GTPase canonical pathway.

IPA networks

ADC. For the margin vs. center comparison, IPA indicated two networks: (i) cellular movement, hematological disease, and immunological disease, consisting of 10 proteins, and (ii) cell death and survival, cellular movement, and organismal injury and abnormalities, consisting of seven proteins. The cellular movement, hematological disease, immunological disease network is shown in Fig 6A, overlaid with signaling by the Rho GTPase canonical pathway.
pathway. The center vs. control comparison indicated four networks: (i) cellular movement, hematological disease, and immunological disease, consisting of 22 proteins; (ii) cell death and survival, connective tissue disorders, and free radical scavenging, consisting of 15 proteins; (iii) cancer, endocrine system disorders, and organismal injury and abnormalities, consisting of seven proteins; and (iv) cell death and survival, embryonic development, and post-translational modification, consisting of two proteins. The cellular movement, hematological disease, immunological disease network is shown in Fig 6B overlaid with the epithelial adherens junction signaling canonical pathway.

For the margin vs. center comparison, IPA indicated two networks: (i) connective tissue disorders, post-translational modification, and protein folding, consisting of 17 proteins, and (ii) cell morphology, embryonic development, and hair and skin development and function, consisting of three proteins. The connective tissue disorders, post-translational modification, protein folding network is shown in Fig 7A overlaid with HIF 1α signaling canonical pathway. The center vs. control comparison indicated five networks: (i) cell morphology, embryonic development, and hair and skin development and function, consisting of 20 proteins; (ii) carbohydrate metabolism, cellular movement, and hematological disease, consisting of 16 proteins; (iii) cancer, gastrointestinal disease, and hepatic system disease, consisting of 12 proteins; (iv) cardiovascular disease, cell death and survival, and molecular transport, consisting of seven proteins; and (v) cancer, organismal injury and abnormalities, and renal and urological disease, consisting of five proteins. The cell morphology, embryonic development, hair and skin development and function network is shown in Fig 7B overlaid with glucocorticoid...
receptor signaling canonical pathway. The margin vs. control comparison indicated the same networks as the center vs. control comparison overlaid with glucocorticoid receptor signaling (Fig 7C).

Compared of SCC and ADC

Venn diagrams and the results of the enrichment analysis performed across the tested comparisons for SCC and ADC are presented in Fig 8. Unique proteins were identified for the center vs. margin comparison (20 for SCC and 17 for ADC); however, no common proteins were identified (Fig 8A). On the other hand, the center vs. control and margin vs. control comparisons revealed 19 and 21 common proteins, respectively (Fig 8A). Among them, 16 proteins were common to both cancer subtypes, while three (calreticulin (CALR), eukaryotic translation elongation factor 1 gamma (EEF1G), and YWHAZ protein (YWHAZ)) were unique for center vs. control and five (citrate synthase (CS), heat shock 70 kDa protein (HSPA1A), mitochondrial heat shock 60 kDa protein (1 HSPD1), PPA1, and inorganic pyrophosphatase (PPIA)) were unique to margin vs. control. In addition, several unique proteins were detected in each comparison: center vs. control: 44 proteins unique to SCC and 28 to ADC; margin vs. control: 52 proteins unique to SCC and 26 to ADC.

Simultaneous pathway, disease, and function enrichment analyses of two tested subtypes of NSCLC are shown in Fig 8B and 8C. The proteins in SCC and ADC enriched similar canonical pathways or diseases and functions; however, some unique patterns could
also be observed. In general, greater p-values for canonical pathways were noted for SSC, but some exceptions were identified (Fig 8B). For center vs. control and margin vs. control comparisons, acute phase response signaling and iron homeostasis signaling were more pronounced in ADC. Disease and function comparisons for margin vs. control revealed opposite predicted activation states for functions related to cell movement and migration, activated in SCC and inhibited in ADC (Fig 8C). The invasion of cells was activated in SCC according to both comparisons and inhibited in ADC (Figs 8C and 9A). The reverse activation state was detected for cellular infiltration (Figs 8C and 9B). Among the top 20 diseases and functions, the inhibition of leucocyte chemotaxis was only identified in the center vs. control (z-score = -2.177, -2.159) and margin vs. control (z-score = -1.941, -1.673) comparisons for ADC.

To further investigate protein–protein interactions within tumor tissue, we performed STRING analysis, taking into account only unique proteins identified in the center vs. margin comparison in SCC and ADC. Even though there was no overlap in proteins between the two subtypes of NSCLC, some proteins were associated with similar pathways in the center vs. margin comparison (Fig 10). Among the top five GO biological processes, leucocyte activation, involved in the immune response (FDR = 5.36E-05) and vesicle-mediated transport (FDR = 7.80E-4), was enriched by 10 (4 SCC/6 ADC) and 13 (8 SCC/5 ADC) proteins, respectively. The second most enriched biological process, the interleukin-12-mediated signaling pathway (FDR = 5.36E-05), was enriched by five proteins (2 SCC/3 ADC).
In this study, we identified, for the first time, several proteins differentially expressed between the tumor center and margin in both ADC and SCC. For some proteins, different proteoforms were also identified. For each lung cancer subtype, a different set of specific proteins was found to be involved in a variety of mechanisms of cancer progression. Therefore, cancer progression in the two lung cancer subtypes may be related to different mechanisms. We also identified several proteins differentially expressed between the control and margin or center of ADC and SCC that could be potential biomarkers for tumors. IPA indicated several canonical pathways and numerous categories related to cancer, including lung cancer. Several proteins detected in our study belonged to “high-abundance” category, including hemoglobin, cytoskeletal, keratins, HSP’s, metabolic and other housekeeping proteins, components of the translational machinery. This likely reflects the limitations of resolving power of 2D-DIGE.

Proteins related to cancer invasion expressed in ADC tumors

**Margin vs. center.** In this study, we identified several proteins specifically linked to lung cancer invasion and progression. The invasion of cells was also indicated by bioinformatics analysis (see Figs 8 and 9). LMNAs, proteins in the nuclear matrix, were recently associated with lung cancer development and metastasis via epigenetic mechanisms [37]. MSN is a [37].
member of the ezrin–radixin–moesin family of proteins involved in various aspects of cell migration, adhesion, and invasion [38, 39], and DPYSL3 and heat-shock chaperonin (HSP60) were linked to lung cancer metastasis [40, 41]. Moreover, CCT was found to be a biomarker of cancer progression and related to the survival of lung cancer patients [42, 43]. A similar role was attributed to ALDH2 for lung and liver cancer patients [44]. The latter has also been linked to chemotherapy resistance [45], whereas TUBB is recognized as a cellular target for chemotherapeutic agents and a marker of centrosome abnormalities in lung cancer [46, 47]. Both TUBB and LGALS1 are involved in podosome assembly, as indicated by GO and STRING analysis. Podosomes are invasive or degenerative structures involved in the degeneration of the extracellular matrix (ECM). Podosomes are found in normal cells as well as cancer cells (named invadosomes) [48, 49]. Subunits of proteasome alpha have been found to participate in the malignant progression of several human cancers, including lung cancer [50], and the inhibition of these subunits was found to be a promising strategy for the radiosensitization of non-small-cell lung cancer [51]. CS, an enzyme of the tricarboxylic acid cycle, has been recognized as an important factor in the progression of cancer pathogenesis and was found to be a marker of chemoresistance in non-small-cell lung carcinoma [27]. Elevated levels of CS were also found in bronchoalveolar lavage fluid from lung adenocarcinoma cancers [52]. CA1 was recognized as a promising biomarker for the early detection of non-small-cell lung cancer in both sera [53] and lung cancer tissues [54, 55]. It is worth to mention that APOA1 was indicated in the recent study [56] to have a prognostic potential to be used in the progression of obstructive pulmonary disease (COPD) to lung cancer.
Tumor vs. control comparisons for ADC. The bioinformatic analysis of the margin vs. control proteins clearly supports the role of differentially expressed proteins in the invasion of cells. It is interesting that this analysis provided different sets of proteins than the margin vs. center comparison (with the exception of LMNA; see above). The analysis indicated six upregulated and six downregulated proteins in the margin. These proteins should be targeted for future studies aimed at better understanding ADC tumorigenesis, especially HSP90AB1, which is a potential marker of ADC (see below). It is interesting to note that this analysis did not indicate any predicted activation relationships; rather, relationships related to inhibition (for seven proteins: LMNA, NME1, PKM, S100A4, SERPINA1, VIM, and AHCY) were indicated for both increased and decreased proteins in the tumor (see Fig 9A). These results are currently difficult to interpret but may indicate the complex nature of cell invasion in ADC. Contrary to the analysis of the invasion of cells, the analysis of ADC cellular infiltration clearly indicated the predicted activation of this pathway in ADC for six proteins (ALB, ANXA2, APOA1, PPIA, SERPINA1, and AKR1B1); interestingly, most of the proteins were decreased in the tumor, with the exception of AKR1B1. In addition to APOA1 (see above) also FGB, HP and SERPINA1 were found to be involved in progression from COPD to lung cancer [56]. SERPINA1 was proposed to be useful to monitor evolution of NSCLS reflecting individual cancer progression [57]. In summary, proteins identified in adenocarcinoma patients are associated with several aspects of cancer progression.
invasion and progression, including cell migration, adhesion and invasion, cytoskeleton structure, protein folding, and metabolism. This knowledge should provide a foundation for future detailed studies aimed at unraveling the mechanisms of ADC tumorigenesis in detail. In our analysis we have found inconsistent finding with state of downstream molecule (yellow lines present in Fig 9). We would like to emphasize that the inconsistencies were also observed by other scientist when IPA was applied for cancer proteome analysis [58–63].

**Proteins related to cancer invasion expressed in SCC tumors**

**Margin vs. center.** Similar to ADC, several proteins specifically linked to cancer invasion and progression were identified, with a wide variety of possible mechanisms. PRDX4 was found to promote human lung cancer progression via the modulation of specific phosphokinase signaling [64]. LDHA in solid tumors was found to be linked to aggressive cancer, which is related to its upregulation due to hypoxia [65]. A recent meta-analysis indicated that high LDH levels might be associated with poor prognosis in lung cancer [66]. Another glycolytic enzyme, PKM, is associated with poor prognosis in non-small-cell lung cancer [67, 68]. Recent studies have indicated a relationship between KRT19 and the aggressive and metastatic dissemination of lung adenocarcinoma [69]. This suggests that KRT19 can be used for the evaluation of both SCC and ADC [70]. A similar relationship was also found for KRT5.

ERO1A is a major regulator of disulfide isomerase, which was found to be a prognostic indicator of NSCLC [71]. EHD1, a member of a family of highly conserved proteins involved in regulating endocytic recycling, is strongly linked to poor survival for lung cancer patients [72–74]. It is possible that the role of EHD1 in tumor progression is related to its role in tumor angiogenesis [75, 76]. RUVBL1, a novel C-RAF-binding protein, was found to promote lung cancer tumorigenesis through the activation of the RAF/MEK/ERK pathway [77]. CTSD, a lysosomal protease, has long been recognized as a SCC biomarker [78, 79]. However, CTSD was also found to be a potential prognostic marker for ADC [80]. ARHGDIB was found to be a suppressor of the migration and invasion of human lung cancer [81, 82]. An interesting finding revealed by STRING analysis indicates vesicle-mediated transport as an important factor in SCC tumorigenesis. Extracellular vesicles play an important role in cancer metastasis via their export to target organs [83]. Exosomes are also recognized as potential regulators of intracellular communication in cancer and are involved in several processes important for cancer progression [84]. As such, they are viewed as part of a series of not linear, but rather concurrent partially overlapped processes critical for metastasis [85]. A progression from COPD to lung cancer was also indicated for TF and for APOA1 [56]. Moreover, exosomal proteins can contain information about tumor identity and most importantly can be involved in regulating of tumor progression and growth [86].

**Tumor vs. control comparison in SCC.** The bioinformatic analysis of the margin vs. control proteins in SCC clearly supports the role of differentially expressed proteins in the invasion of cells. The analysis indicated 17 upregulated and one downregulated protein in the margin. It is interesting to note that, contrary to the case for ADC, this analysis indicated 13 predicted activation relationships and no inhibition at the same time. This strongly points to the importance of the invasion of cells in SCC tumorigenesis. Contrary to the analysis of the invasion of cells, the analysis of SCC cellular infiltration did not indicate the predicted activation of this pathway; however, 13 proteins were indicated as participating in this pathway, mostly via increases in their concentrations (10 proteins).
Canonical pathways and diseases or functions related to ADC tumor margin and center

The canonical pathway analysis revealed several pathways related to cancer progression. Two canonical pathways related to Rho signaling were identified in our study as being involved in signaling mediated by the Rho GTPase family. Rho GTPases are small GTPases involved in the regulation of the actin cytoskeleton, cell migration, and stem cell differentiation [87]. Consequently, their activity is strongly linked to cancer invasion, including that in lung cancer [88]; their main mechanisms of action are thought to be the formation of dynamic actin-rich protrusions and their role in the turnover of cell–cell and cell–extracellular matrix adhesions [89, 90].

Semaphorins, a family of proteins initially characterized as axon guidance factors, have recently been implicated in several physiological functions, such as immune responses and angiogenesis [91]. Recent evidence suggests that semaphorins are important in the etiology of several forms of cancer [92–94]. There are multiple mechanisms by which semaphorins promote tumor progression, including their effects on angiogenesis and lymphangiogenesis, and direct effects on tumor cells [94]. Recent reports indicate that semaphorins are involved in epithelial–mesenchymal transition (EMT), which is associated with cancer cell heterogeneity, plasticity, and metastasis. Notably, MYL3 and DYPSL3 were upregulated in the tumor center, which strongly suggests the importance of these proteins in the center’s characteristics. It is also interesting to note the association of semaphorins with the RhoA signaling pathway [95, 96]. This signaling pathway is also involved in epithelial adherens junctions (AJs), indicated in our analysis, which are part of the mechanism binding epithelial cells together [97]. It is of interest that both molecules involved in AJs, MYL3 and TUBB, are upregulated in the tumor center, which may be important for AJs in this region. The disturbance of AJs with a loss of epithelial features and gain of mesenchymal phenotype is a typical feature of EMT [98].

The ubiquitin system is conserved in eukaryotes; its main role is the degradation of proteins, but it also plays numerous roles in signal transduction, cell–cell progression, receptor trafficking and endocytosis, and immune responses. The ubiquitination of proteins is a common post-translational modification in most cell types. Disturbances of ubiquitin-mediated processes often result in tumorigenesis and metastasis, including lung cancer [99–101]. Ubiquitination is part of the mechanism leading to the dissociation of AJs during EMT [97]. The upregulation of HSPD1 and PSMA1, the molecules involved in ubiquitination, in the margin suggests that protein turnover is important for ADC progression.

Agranulocyte adhesion and diapedesis belong to the immune/inflammatory-related canonical signaling pathway and are recognized as the primary line of host defense against infection [102]. This pathway has been indicated to be involved in cancer invasion and metastasis in breast and lung cancer [103, 104]. The exact role of agranulocyte adhesion and diapedesis in cancerogenesis is not clear at present; it may be involved in immune-related mechanisms, such as the development of the tumor microenvironment [105], or extracellular matrix remodeling to promote mesenchymal shift and cell transformation [106]. Our results indicate that the molecules involved in this pathway (MSN and MYL3) are either upregulated or downregulated in the margin and center, which suggests the importance of agranulocyte adhesion in both parts of the tumor.

Biogenic amines have been linked to cancer cell growth [107]. Phenylethylamine degradation was indicated as a canonical pathway in our study, and this pathway was shown to be related to drug resistance in various cancer cell lines [108]. However, to our knowledge, phenylethylamine degradation has not yet been linked to lung cancer. Further studies should explore the role of this pathway in lung cancer development.
In summary, we identified several canonical pathways related to tumor progression. These pathways often overlap, indicating their involvement in several specific mechanisms of ADC tumorigenesis. Important physiological phenomena related to cancer invasion were identified, especially including EMT and AJ s. Moreover, the functional categories highlight functions related to cell death and survival and cell movement, which indeed are related to cancer invasion. Several proteins were categorized to different cancers, which strongly suggests that they are part of a general mechanism of carcinogenesis. It should be underlined that all signature pathways were predicted by <5 molecules therefore further studies are necessary to validate our results by other analytical approaches, such as IHC, WB, or ELISA.

**Canonical pathways and diseases or functions in SCC tumor margin and center**

The canonical pathway analysis of the SCC tumor margin and center revealed pathways related to cancer progression and metabolism. HIF-1α signaling, identified in our study, is involved in the adaptive response of cells to hypoxia through a switch in cell metabolism from aerobic to anaerobic (Warburg effect) [109]. It is worth mentioning that two proteins indicated by this pathway, LDH and TF, were upregulated in the center, whereas a third, PKM, was upregulated in the margin, which may reflect the metabolic specificity of the tumor parts. Hypoxia (a reduced amount of oxygen in the cancer microenvironment, below 10 mmHg of O₂) is a characteristic feature of several cancers and was found to be linked to a number of features of tumor invasion and metastasis, e.g., EMT, the tumor cell invasion of the basement membrane and ECM, cell motility, angiogenesis and lymphangiogenesis, and extravasation [110]. Overall, these results suggest that a switch in metabolism is an important feature that discriminates the margin and center of SCC tumors. This is supported by the identification of the pyruvate-to-lactate pathway, which is an indication of anaerobic metabolism. It is also interesting that EMC and metastasis has been linked to N-acetylglucosamine (a pathway indicated in this study) via its involvement in post-translational modifications of proteins important for tumorigenesis [111].

Phagosome maturation is related to autophagic processes in tumor cells, which may be related to antitumor action, especially in the earlier stages, or may facilitate tumor progression, especially in the later stages [112]. This agrees with our results indicating the upregulation in the tumor margin of both CTSD and NAPA, which are present in the phagosome maturation pathway. The enrichment of phagosome maturation was observed in NSCLC cells exposed to cigarette smoke [113]. Pathways related to neurodegenerative diseases, such as Huntington’s disease (HD), have been described in metastasis-derived breast cancer cells, which suggests an association between cancer and HD [114]. Our results suggest a similar relationship in lung cancer, which is in agreement with the results of Moreira Sousa et al. [115].

The proper expression of glucocorticoid receptors (GRs) is essential for the normal development of the lung, and the disruption of its expression is linked to cancer development [116]. The tumorigenic action of GR is associated with tumor cell invasion and lung metastasis, leading to EMT induction [117]. On the other hand, GR was also identified as a tumor suppressor gene via regulation mitotic progression [118]. Interestingly, CTSD was also indicated as a molecule related to the biosynthesis of thyroid hormone. A link between lung cancer and thyroid hormone synthesis was indicated decades ago [119]. Its mechanism of action has been linked to the proliferative activity of lung cancer cells via nongenomic action [120]. Moreover, the influence of thyroid hormone drives tumor cell proliferation and survival as well as angiogenesis [121], which links thyroid hormone with HIF-1α signaling indicated by IPA (see above). It is also interesting that thyroid hormone signaling was indicated by microRNA analysis as a pathway enriched in NCLS [122].
Upstream regulators in ADC and SCC

In our study we employed IPA Upstream Regulator analytic tool which is focused on the identification of the cascade of upstream transcriptional regulators that can explain the observed gene expression changes in our dataset, which can identify the biological activities occurring in the tumor and control tissues. IPA’s definition of upstream transcriptional regulator is quite broad—and include “any molecule that can affect the expression of other molecules”, which means that upstream regulators (or “transcriptional regulators” as they are referred to in this document) can be almost any type of molecule, from transcription factor, to microRNA, kinase, compound, or drug”. Indeed, in our study apart from transcription regulators other compounds were identified as upstream regulators, including proteins (translation regulators, hormone precursors, and enzymes), long non-coding RNAs, several hormonal small molecules, and synthetic or exogenous origin molecules.

Transcription regulators. Several upstream regulators were found for center or margin as compared to control both for ADC and SCC. NFE2L2, MYC and MYCN (the later found only for ADC) were identified as activated transcription regulators in our study. The Myc proto-oncogene family (reviewed recently by Wang et al. [123]) consists of three members, C-MYC, MYCN, and MYCL, which encodes the transcription factor c-Myc, N-Myc, and L-Myc, respectively. Diverse mechanisms of aberrant MYC pathway activation in human cancers were identified [124]. MYC transcriptionally activates several hundred target genes that participate in diverse biological processes. Myc oncoproteins are involved in several physiological processes, including cell proliferation, differentiation, survival, and apoptosis. Being the main regulator of cellular oxidative stress, NFE2L2 is redox-sensitive transcription factor which controls the expression of several genes with cytoprotective and antioxidant function, and interestingly can be also controlled by microRNAs [125]. Genes in the KEAP1-NFE2L2 pathway are mutated in ~33% of lung squamous cell carcinoma and ~22% of lung adenocarcinoma [126], which agrees with our results indication the presence of NFE2L2 as activated upstream regulator both in ADC and SCC.

Other proteins. Our results also revealed the presence of upstream regulators proteins other than transcription regulators. These proteins belong to several groups, including translation regulators, hormone precursors, and enzymes. LARP1, KDM8 and STK11 were indicated as upstream regulators only in ADC. LARP1 is RNA-binding protein and a member of the LARP family which regulates both mRNA translation and stability and functions as an oncogene in non-small cell lung carcinoma [127]. At a functional level, LARP1 promotes cell migration, invasion, anchorage-independent growth, and in vivo tumorigenesis [128]. It should be underlined however that upstream regulators analysis indicated that LARP1-mediated pathway is rather inhibited in the center of ADC tumor (negative z-score for center vs. control comparison). Further studies should establish the dynamic of LARP1 upstream regulator in relation to position of cancer cells within the tumor.

KDM8 is involved in epigenetics modifications of genetic information via histone methylation. Several studies have shown that KDMs disorders play an important role in malignant tumors, including lung cancer [129, 130]. Interestingly, KDM8 has been linked to hypoxia-driven epigenetic regulation in cancer progression [131]. STK11 protein plays a role in the metabolism of lipids, glucose, and cholesterol by activating the AMP-activated protein kinase [132]. STK11 is recognized significant gene in cancer which induces tumor heterogeneity, promotes different responses to therapies [133] and is among the most often mutated genes in lung adenocarcinoma [134].

CLPP is located in the mitochondrial matrix. CLPP is an oligomeric serine protease that is similar to the cytoplasmic/nuclear proteasome and plays a central role in mitochondrial
protein quality control by degrading misfolded proteins [135]. CLPP is overexpressed in several cancers, including NSCLC [136]. It should be underlined that for CLPP z-score was negative similarly to LARP1 (see above).

**Long non-coding RNAs.** Long non-coding RNAs (lncRNAs) are transcripts without the protein-coding capability with more than 200 nucleotides in length that are mainly generated from gene introns, intragenic regions, promoter regions of coding mRNA, antisense strands of mRNAs and pseudogenes. LncRNA PCGEM1 found in ADC only as activated upstream regulator, plays an important oncogenic role in cancer progression [137] and is widely implicated in a variety of human cancers, including lung cancer [138, 139].

**Small molecules.** *Natural.* The upstream regulators can also be a small molecule that affect gene expression in some direct or indirect way [140]. Our analysis indicated several hormonal small molecules as both inhibited (negative z-score) and activated (positive z-score) upstream regulators. For ADC L-triiodothyronine has been identified as negative upstream regulator. It is well known that thyroid hormone signaling is interrelated with lung cancer in a dual manner, either promoting or inhibitory [141] and our results suggest the latter is true for center of the tumor as compared to the margin. Identification of insulin as upstream regulator in SCC points out well described relationship between diabetes mellitus and cancers, including lung cancer, and hyperinsulinemia and exogenous insulin and insulin analog therapy were indicated as common risk factors for development of cancer [142].

Identification of IL15 as activated upstream regulator for ADC agrees with the knowledge that inflammatory pathways are implicated in lung cancer development [143] and IL15-mediated cross-talk between patrolling monocytes and NK cells is involved in metastasis formation [144]. Testosterone, indicated in our analysis as activated for ADC, has been found to be related to several cancers and its action is related to gender [145]. Moreover, testosterone acts as a precursor for local estrogen production within lung tumors, independent of reproductive organs [146, 147]. Our results also clearly indicated β-estradiol as activated upstream regulator for SCC. Similar to testosterone, estrogen actions were found to contribute to female gender-specific risks in the development of lung carcinoma [148]. The mechanism of estradiol tumorigenesis has been linked to its interaction with estrogen receptors that have been detected in lung cancer cells [149].

**Synthetic or exogenous origin.** We identified small natural-like synthetic compounds, namely biphenyl and terphenyl compounds for ADC, such as: IND S1, IND S7 and MEL S3 [150] that has been pointed out as involved in resistance in cancer cells [151] and 5-fluorouracil is well-known chemotherapeutic agent [152]. On the other hand, sirolimus and lipopolysaccharide were identified as upstream regulators for SCC. Sirolimus is macrocyclic lactone of bacterial origin and is immunosuppressive agent for considerable improvements in acute and chronic organ rejection and the life expectancy of transplant recipients [153]. Its mechanism is related to the phosphatidylinositol 3-kinase (PI3K)/Akt pathway and reduction of angiogenesis important for cancer development [154]. Lipopolysaccharide-induced tumor necrosis factor-α factor enhances inflammation and is associated with cancer [155].

Our analysis identified three synthetic retinoids as upstream regulators for SCC, ST1926, tretinoin, and CD437. ST1926 is synthetic retinoid tested for prevention or treatment of certain types of cancer [156, 157]. ST1926 has shown efficacy against several solid tumor models including lung carcinoma [158]. Another synthetic retinoid–tretinoin has also been used advanced in lung cancer studies [159]. CD437 is toxic to numerous cancer cell lines, including NSCLC cancer via induced apoptosis [160, 161]. We have also identified 1,2-dithiole-3-thione, which is organosulfur compound cancer chemopreventive agent. The key mechanism of action of dithiolethiones involves activation of Nrf2 signaling and induction of phase II enzymes [162].
6-OHDA was found as upstream regulator only in SCC. 6-OHDA was found to induce secretion of PARK7/DJ-1 which is a Parkinson disease- and cancer-associated protein that functions as a multifunctional protein involved in gene transcription regulation and anti-oxidative defense [163].

In summary, our analysis revealed several potential upstream regulators of different nature for future studies of the mechanism for ADC and SCC carcinogenesis. Both common and different upstream regulators were identified for both cancer types, for example testosterone for ADC and β-estradiol for SCC. This knowledge can be helpful for better understanding of specificity of ADC and SCC development.

**Differences between tumor margin and center can be explained by a “relay race” model**

In our opinion, the results obtained in this study indicating significant differences between the tumor margin and center may be related to differences in the specific metabolisms of these tumor parts. Giatromanolaki et al. [35] proposed the “relay race” model of tumor vascular growth and regression. These authors indicated an extreme difference between the tumor center, with a prevalence of unfavorable environmental conditions, including hypoxia, acidity, and apoptosis (also indicated in our study), accompanied by a decrease in angiogenesis and a shift in metabolism to anaerobic glycolysis. This suggestion is also supported for ADC (but not SCC), in which the activation of necrosis in the tumor center was indicated by IPA. This is the opposite of the case for the tumor margin, where the conditions for growth are favorable for proliferation and angiogenesis. The vascularization of such tumors is known as an “edvin” (“edge vs. inner”) design [35]. The edvin type of tumor vascularization was also attributed to non-small-cell lung cancer [164].

As expected, and as shown in our study, the differences in anatomical and environmental features between the tumor margin and center have to be reflected in differences in biochemical characteristics, including proteins and/or their proteoforms. For example, González et al. [165] demonstrated differences between the invasive margin and breast tumor core in the expression of matrix metalloproteases and their inhibitors on mononuclear inflammatory cells. The results of our study provide detailed information concerning several proteins differentiating the tumor margin and center.

Moreover, comparative IPA indicated pathways that may reflect differences in the microenvironment of either ADC or SCC tumors. For example, canonical pathways (see Fig 8) indicate the importance of glucocorticoid receptor signaling, glycolysis, HIF-1α signaling, the iron homeostasis signaling pathway, and hypoxia signaling in the cardiovascular system for SCC, and aldosterone signaling in epithelial cells, 14-3-3-mediated signaling, and the xenobiotic metabolism AHR signaling pathway for ADC. Disease and function IPA of SCC highlighted activation of morbidity or mortality and the migration of tumor cell lines activation in the tumor center, with the concomitant suppression of cell survival and apoptosis. On the other hand, for the ADC tumor center, the activation of the cell death of tumor lines, necrosis, and apoptosis were indicated, with the concomitant suppression of viral infection and apoptosis of tumor cell lines. The importance of particular pathways is not currently clear, especially in light of the contradictory results; for example, apoptosis in ADC was indicated to be both activated and suppressed in the tumor center. In our opinion, these results open a new area of research focusing on a detailed analysis of biochemical and physiological pathways and the mechanisms related to the dynamics of tumor development. Such detailed studies are also justified by the need for the biochemical profiling of tumor development and identification of potential biomarkers.
Post-translational modifications

Post-translational modifications are important modifications of protein structures that cannot be predicted from genomic analysis alone but are important for the development of cancer [166]. Several PTMs can be identified using two-dimensional electrophoresis, mainly those resulting in changes in protein mass or charge. Recently, using 2D-DIGE, we identified several proteoforms of blood plasma proteins from lung cancer patients, including proapolipoprotein, apolipoprotein AIV, clusterin, gelsolin, fibrinogen, haptoglobin, hemopexin, transferrin, and serotransferrin [11]. In this study, several proteins with proteoforms were also identified in the tumor margin and center, including lamin, L-plastin, aldehyde dehydrogenase 2, and carbonic anhydrase 1 for ADC and cyclophilin B for SCC. Indeed, in several studies, these proteins were found to be subjected to numerous PTMs. For example, L-plastin phosphorylation influences its actin binding, which was found to be important for cancer invasion, while S-glutathionylation reduces its binding to actin [111, 167]. Oshita et al. [168] found several proteoforms of ALDH2 and suggested that they underwent post-translational modifications such as phosphorylation, acetylation, and glycosylation. These modified forms may be biomarkers that can be used to predict tumor recurrence in patients with early-stage NSCLC. The activity of carbonic anhydrase can be modified via several reactions, such as phosphorylation, disulfide-bridge formation, S-glutathionylation, S-nitrosylation, O- and N-linked glycosylation, non-enzymatic glycation, acetylation, ubiquitination, glycosylphosphatidylinositol anchoring, and methylation, as reviewed by Di Fiore et al. [169]. That study pointed out the significance of PTMs, often detected at conserved amino acids, and noted the need for further studies to unravel the functional importance of these PTMs in both physiological and pathological conditions. The dysregulation of functional networks as a result of PTM variability is clearly recognized as an important factor that needs to be taken into account in the context of biomarker complexity [170]. Our results strongly suggest the need for such an approach in further studies of lung cancer. In our study we used two-dimensional electrophoresis to distinguish protein changes, including those that are likely related to PTMs. We are aware that by using this method we were able to identify only limited number of PTMs as a consequence of restrictions of electrophoresis, namely because only proteins that change their migration on gel (due to changes in protein’s MW and/or charge) could be detected. For example, gene mutations produced by changes in amino acids with similar properties could not be detected in our study and gene and/or protein sequencing are necessary to identify such mutations.

Comparative analyses between control and tumor tissues

Contrary to the comparison between the margin and center of the lung tumor, comparative analyses between the control and ADC and SCC tumor tissues revealed that, besides repetitions of a few proteins identified in the margin and center, several new proteins differentiating the two tissues were identified. Besides individual proteins, four groups emerged: proteins related to hemoglobin (five proteins), heat-shock proteins (12 proteins), eukaryotic translation elongation factors (six proteins), and keratins (six proteins). Among these groups, both proteins upregulated and downregulated in lung cancer tissues were detected. In the next paragraphs, we discuss their importance in cancer studies.

Hemoglobin beta chain. In our previous study, we identified hemoglobin beta chain (HBB) in the blood plasma of lung cancer patients subjected to chemotherapy, which was related to the presence of HBB in erythrocytes [11]. In the current study, four hemoglobins, including alpha and beta chains, were found in lower abundance in both ADC and SCC tissues. These results strongly suggest alternating expression of globin chains in lung cancer cells.

This agrees with recent data obtained utilizing single-cell RNA-seq, showing the induction of...
HBB in breast, prostate, and lung cancer cells [171]. Hemoglobin alpha 1 globin chain (HBA1), identified in our study, was recently shown to be expressed in lung cancer tissues and in the exhaled breath condensate of lung cancer patients [172, 173]. The mechanism of hemoglobin’s action in tumor cells is unknown at present, but it is speculated that HBB can protect tumor cells and their ability to metastasize by controlling ROS inside the cells [174].

Heat-shock proteins. The heat shock protein (HSP) family comprises important, highly conserved molecular chaperones involved in the response to several stress conditions, such as heat induction, hypoxia, virus infection, and neoplasia, including lung cancer [175–177]. Among the HSPs identified in our study, we recognized members of the heat shock protein 90 (HSP90) family, including TRA1, HSP90AA1, HSP90AB1, and HSP90B1 [178]; the overexpression of the last has been linked to lung tumor growth, including that in ADC [179–181]. Recently, Klimczak et al. [182] proposed that heat-shock proteins could be used to create signatures for predicting clinical outcomes in breast cancer. Our results clearly demonstrate differences in the occurrence of particular HSPs in ADC and SCC, which suggests that protein signatures based on chaperones may be useful for discriminating ADC and SCC.

Eukaryotic translation factors. Eukaryotic translation factors are key proteins in protein synthesis that have been recently identified as a new class of potential oncogenes acting through reducing the fidelity of protein translation, inducing cytoskeleton alterations, and disrupting signaling pathways [183, 184]. Among the elongation factors in this study, we identified EEF1A1, EEF1A1L, EEF1D, EEF1G, and EEF2. EEF1D and EEF1G have been implicated in lung cancer [184, 185]. EEF2 was found to be a novel tumor-associated biomarker that is overexpressed in various cancer types, including lung cancer [186]. EEF1G was found to be included in a 16-gene expression signature for distinguishing stage I from stage II squamous carcinoma of the lung [187]. It is interesting that HSP90AA1, identified in our study (see above), was also included in that signature. Our results reveal that, besides the previously described elongation factors, initiation factors such as EIF3G and EIF-4II are also involved in lung cancer. To date, these factors have only been attributed to other cancers, such as mesothelioma [188] and colorectal cancers [189].

Keratins. Besides the differential expression of KRT5 and KRT19 between the margin and tumor center, KRT6B, KRT8, KRT10, and KRT17 were identified among the proteins differentiating the cancer from control tissue. KRT6B and KRT10 were found to be abundant in exhaled breath condensate and to be potential biomarkers for the early diagnosis of lung cancer [172]. The expression of KRT8 was found to correlate with KRT19 and was linked to EMT [190], similar to KRT17 [191]. KRT8 was used for cancer prognosis, including for ADC patients [192, 193], whereas KRT10 was found to be a useful biomarker for the treatment response in lung cancer [194]. Keratins appeared to be subjected to post-translational modifications when they were expressed in tumors [195, 196].

Proteins upregulated in cancer tissues with high fold changes compared to control

In our study, several proteins of cancer tissues were upregulated with high fold changes compared to control tissues, which makes them possible candidates as tumor biomarkers. The complete list of these proteins is presented in S1 and S2 Tables, and here, we describe potential major biomarkers (selected based on fold changes >5). For ADC, such proteins include HSP90AB1 and HSPD1, which belong to the heat-shock family described above, a major protein group expressed in tumor tissues. Interestingly, the combination of CALR and disulfide isomerase (PDIA3) was found to be a potential prognostic biomarker for non-small-cell lung
cancer [197], which coincides with our finding of the upregulation of PDIA4 in ADC and PDIA3 and PDIA4 in SCC tissues.

Similar to ADC, several proteins were attributed to all of the above-mentioned protein groups: heat-shock proteins, eukaryotic translation factors, keratins, and hemoglobin beta chain. Other proteins detected in our study reflect further important functions related to tumorigenesis. For example, ezrin has been linked to cancer invasion and progression as a member of the ezrin–radixin–moesin family of proteins involved in various aspects of cell migration, adhesion, and invasion (see above). In our study, alpha tubulin (TUBA1B) was found to exhibit a high fold change compared to control in SCC samples. It is worth mentioning that beta tubulin was also identified in ADC samples (see above), which strongly supports the universal significance of microtubules for tumorigenesis. Our results suggest potential prognostic value of identified proteins which calls for further studies on larger group of patients and the uses of biostatistical calculations between candidate proteins with various clinicopathological factors.

Tyrosine 3 monooxygenase/tryptophan 5-monooxygenase activation protein zeta (YWHAZ, also named 14-3-3ζ) was identified as a central hub protein for several transduction pathways, with a significant role in tumor progression [198]. YWHAZ is involved in promoting EMT and lung cancer metastasis [199] and was found to be a reliable prognostic biomarker for NSCLS [200]. In addition, 14-3-3 signaling was also indicated by the IPA of our results.

Ingenuity canonical pathways of the ADC and control samples revealed numerous canonical pathways of disease and function for both the margin vs. control and center vs. control comparisons. Some of these categories, such as acute phase response signaling, glycolysis I, and the iron homeostasis signaling pathway, are the same and others differ, which suggests that it is possible to discriminate between markers from different parts of the tumor. Most of these pathways are linked to tumorigenesis and are in agreement with the information discussed above concerning the characterization of the tumor margin and center. A chronic inflammatory-like state is regarded as a hallmark of cancer and is associated with cancer development and disease progression, including that of lung cancer [201]. Glycolysis and HIF-1α signaling (also identified in SCC tumors; see below), which were indicated in our study, are often linked together, because the HIF-1α pathway plays a vital role in tumor cell survival by redirecting glucose metabolism from oxidative phosphorylation to glycolysis [202]. This issue was discussed above.

Contrary to ADC, the IPA of SCC revealed a very high similarity between the tumor center vs. control and margin vs. control comparisons. This difference between the ADC and SCC analyses is difficult to explain; we think that it could stem from differences in the tumor structure and/or the composition of the control samples. Some major canonical pathways were also identified (and described) for SCC, including glucocorticoid receptor signaling, aldosterone signaling in epithelial cells, and PKR acting in interferon induction and antiviral response. The identification of the sirtuin signaling pathway in our study highlights the importance of post-translational modifications in SCC. Interestingly, sirtuin has also been linked to the regulation of pro-tumorigenic exosomes (indicated by STRING analysis; see above) [203].

Conclusions

Several proteins differentially expressed in the tumor center and tumor margin in ADC and SCC were identified. Proteins differentiating the tumor center and margin were linked to several aspects of cancer invasion and progression, including cell migration, adhesion and invasion, cytoskeletal structure, protein folding, anaerobic metabolism, tumor angiogenesis, EMT, AJs, and inflammatory responses. We identified several new proteins differentiating tumor
and control tissues, including ones that showed high fold changes, which makes them possible candidates for tumor biomarkers. This suggestion should be supported in the future by analyzing an independent validation set.

### Materials and methods

#### Sample collection

The study was conducted in accordance with the Declaration of Helsinki and approved by the local ethics committee of the Medical University of Bialystok (No. R-I-002/36/20014). Table 7 shows the clinical characteristics of the patients included in this study. Informed consent was obtained from 8 ADC patients (5 men and 3 women; age range, 54–78 years; mean age, 67.2 ± 7.1 years) and 7 SCC patients (4 men and 3 women; age range, 58–81; mean age, 68.4 ± 8.2 years). Tissue specimens from tumor center and margin were collected according to the standard operating procedure of the oncological biobank and the procedure described by Niemira et al. [6]. The details of tissue samples collection in the clinical setting–macroscopic evaluation of resected specimen is presented in S9 Material. In brief, after lung tumor resection, whole specimen was examined macroscopically by the pathologist to determine the exact tumor localization, presence or absence of macroscopic residual tumor, presence or absence of macroscopic infiltration of pulmonary pleura, macroscopic evaluation of possible presence of necrosis in the tumor center. Pathologist cut the exact tissue samples that represent the tumor center and tumor margin. Moreover, pathologist determine the possibility to collect adjacent pulmonary tissue (referred as normal tissue) if the distance from the tumor border was greater than 2 centimeters, pathologist was cutting the samples of adjacent tissue. Then, Study Nurses from Biobank were putting the tissue samples alternately into cryotubes for vapour phase of liquid nitrogen (fresh frozen samples) and into tubes with 10% buffered formalin (formalin-fixed samples).

Histopathological analyses were performed once more by a physician with pathomorphological expertise to confirm the diagnosis of ADC or SCC or the presence of non-malignant lung tissue. The details of microscopic evaluation of fresh frozen and formalin-fixed paraffin-

### Table 7. Clinical and pathological characteristics of ADC and SCC patients whose samples were included in this study.

| Tumor type | Age | Gender | Stage | TNM classification | Smoking habit | Histology of control tissue |
|------------|-----|--------|-------|--------------------|---------------|----------------------------|
| ADC        | 70  | F      | IIb   | pT2b pN1 cM0       | Smoker        | Focal atelectasis           |
| ADC        | 64  | M      | Ib    | pT2a pN0 cM0       | Ex-smoker     | Hemosiderin-laden macrophage deposits, atelectasis |
| ADC        | 71  | M      | Ib    | pT2a pN0 cM0       | Smoker        | Fibrosis, hemosiderin-laden macrophage deposits, atelectasis |
| ADC        | 68  | F      | IIb   | pT2b pN1 cM0       | Smoker        | Focal atelectasis           |
| ADC        | 54  | M      | IIIa  | pT3 pN0 cM0        | Smoker        | Fibrosis, hemosiderin-laden macrophage deposits, atelectasis |
| ADC        | 78  | F      | Ib    | pT2a pN0 cM0       | Smoker        | Atelectasis, pneumaticosis, focal fibrosis |
| ADC        | 70  | M      | Ia3   | pT1c pN0 cM0       | Smoker        | Fibrosis, atelectasis       |
| ADC        | 63  | M      | IIIa  | pT4 pN0 cM0        | Smoker        | Emphysema, pneumaticosis    |
| SCC        | 71  | F      | IV    | pT2b pN0 pM1a      | Ex-smoker     | Fibrosis, atelectasis, pneumaticosis, inflammatory cell infiltration consisted of lymphocytes |
| SCC        | 81  | M      | IIa   | pT2b pN0 cM0       | Ex-smoker     | Emphysema, pneumaticosis, congestion |
| SCC        | 63  | F      | IIa   | pT2b pN0 cM0       | Ex-smoker     | Atelectasis, pneumaticosis  |
| SCC        | 68  | M      | IIIa  | pT2a pN2 cM0       | Ex-smoker     | Focal fibrosis, emphysema, congestion |
| SCC        | 76  | M      | IIa   | Not determined     | Ex-smoker     | Focal edema, inflammatory cell infiltration, atelectasis |
| SCC        | 58  | M      | IIb   | pT2a pN1 cM0       | Smoker        | Hemosiderin-laden macrophage deposits, atelectasis, emphysema, congestion and fibrosis |
| SCC        | 62  | F      | IIb   | pT3 pN0 cM0        | Smoker        | Emphysema, pneumaticosis, congestion |

https://doi.org/10.1371/journal.pone.0268073.t007
embedded (FFPE) tissue samples is presented in S9 Material. Quality control and microscopic evaluation were performed for fresh frozen tissue samples and the corresponding FFPE samples. The whole procedure of microscopic quality control of hematoxylin and eosin (H&E) stained tissue sections prepared from fresh frozen tissue samples and FFPE samples was performed by a pathologist, and tissue section preparation was done by the laboratory staff from the Pathology Department. In brief, the preparation of frozen sections were performed from tissues frozen in liquid nitrogen in a cryostat, where cryotissue sections were cut at 5 μm. The microscopic quality assessment of H&E-stained tissue section included following attributes: i) confirmation of the specified organ, ii) histopathological diagnosis compatible with the present H&E section, iii) percentage of tumor content: the epithelial part of the tumor (no tumor stroma), iv) percentage of necrosis (%), v) severity of presence of acellular substance, vi) severity of inflammation, vii) severity of fibrosis, viii) severity of hemorrhage. Following tissue characteristics: acellular substance, inflammation, fibrosis, and hemorrhage were classified according to severity based on a number system (low – 1, medium – 2, high – 3).

For adjacent normal tissue samples (referred as normal tissue), pathologist was ensuring that they contain a representative proportion of organ-specific epithelium or tissue. Normal tissue samples that contained a tumor cells were evaluated as a tumor sample depending on tumor content and tissue quality. The adjacent normal tissue (control tissue) was collected 3–5 cm from the tumor.

Criteria used to distinguish the tumor margin during microscopic evaluation by pathologist included determination of invasive margin and borderline between normal and tumor tissue. Every tissue sample collected from tumor center and tumor margin defined so in the macroscopic evaluation after tumor resection, were examined in the context of intratumoral morphological heterogeneity. Since the width of the peritumoral area was not defined clearly in official standards, in this study and for routine examination of biobanked samples, the tumor margin was characterized within 1 μm. The cancer samples that were verified histochemically contained tumor cell contents of 72.5 ± 15.8 and 71.2 ± 15.8% for the ADC margin and center, respectively, and 80.0 ± 5.8 and 80.0 ± 8.2% for the SCC margin and center, respectively. No tumor cells were found in normal tissue samples; however, several pathological conditions were identified (Table 7). The representative histological pictures of cancer and control tissues were shown in Figs 11 and 12.

### Protein extraction

Proteins were extracted from lung tissue according to a previously described method [5] with some modifications. In brief, fragments of normal tissue and tissues of the tumor center and margin (~100 mg) were sonicated using a VC-13 PB (Sonics, Newtown, CT, USA) set at 35% relative output, for 30 s in 100 μL of extraction buffer (7 M urea, 2 M thiourea, 30 mM Tris, 4% 3-(3-cholamidopropyl) dimethylammonio) 1-propanesulfonate (CHAPS), 100 mM dithiothreitol, 2% (v/v) immobilized pH gradient (IPG) buffer (3–10 NL), 1% (v/v) Triton X-100) containing 1% (v/v) protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA). After sonication, tissue extracts were kept on ice for 1 h and then centrifuged at 12,800 ×g for 20 min at 4˚C, and 200 μg of protein was precipitated using a 2-D Clean-up Kit (GE Healthcare, Uppsala, Sweden). The precipitate was dissolved in labeling buffer (7 M urea, 2 M thiourea, 4% v/v CHAPS, and 30 mM Tris; pH 8.0). The protein concentrations before and after precipitation were measured using a Coomassie Plus Kit (Thermo Fisher Scientific, Waltham, MA, USA) with bovine serum albumin as the standard.
Two independent 2D-DIGE analyses were performed to compare the protein profiles of the normal lung tissue and tissues of the tumor center and margin collected from the ADC patients (n = 8 for each group) and SCC patients (n = 7 for each group). Protein labelling with CyDye DIGE fluor and 2D electrophoresis was performed as previously described by Ciereszko et al. [11]. Aliquots of 50 μg of protein from each sample (normal tissue and tissues of tumor center and margin) were labelled with CyDye DIGE Fluor minimal dyes (GE Healthcare) at a concentration of 400 pmol dye/50 μg of protein according to the scheme presented in S3 and S4 Tables. A dye swap (Cy3/Cy5) was performed between the samples of the control and tumor tissues to exclude dye bias. The internal standard was generated by combining equal amounts of each sample within the experiment and was labelled with Cy2. Differentially labelled samples were mixed together according to the scheme in S3 and S4 Tables and loaded onto Immobiline Dry-Strip gel strips (24 cm, pH 3 to 10 non-linear; GE Healthcare). Isoelectric focusing was performed with an IPGphor isoelectric focusing unit (GE Healthcare), and SDS-PAGE was run using the ETTAN Dalt six electrophoresis unit (GE Healthcare) as previously described [11].

Image acquisition and quantitative analysis

The CyDye-labelled gels were scanned using a Typhoon FLA 9500 instrument (GE Healthcare). After the multiplexed images were acquired, image analysis was performed with the use of DeCyder differential analysis software (version 5.0; GE Healthcare). Intragel spot detection and quantification and intergel matching and quantification were performed using differential in-gel analysis. During spot detection, the estimated number of spots was set at 10,000, and the volume, <30,000. Only spots that were successfully matched on >80% of the gel images were considered. To properly select and identify the spots, the DIGE gels were stained using

Fig 11. Microscopic features of lung adenocarcinoma (figures A to B and D to E) following hematoxylin and eosin staining. (A) Whole slide image of tissue collected from the margin of tumor diagnosed as pulmonary adenocarcinoma. (B) Whole slide image of tissue collected from the center of tumor diagnosed as pulmonary adenocarcinoma. (C) Whole slide image of tissue collected from non-tumor tissue referred as normal tissue. (D) Region of interest: magnification 20x. Lung adenocarcinoma with mixed subtypes–sample collected from tumor margin. A tumor content of 90% was determined by the pathologist and can be seen in the slide scan. (E) Region of interest: magnification 20x. Lung adenocarcinoma with mixed subtypes–sample collected from tumor center. A tumor content of 90% was determined by the pathologist and can be seen in the slide scan. Dust-laden macrophages were marked with solid arrows. (F) Region of interest: magnification 20x. Lung parenchyma–sample collected from non-tumor tissue referred as normal tissue. Numerous hemosiderin-laden macrophages can be seen in this sample and the examples of these cells are marked with asterisks.

https://doi.org/10.1371/journal.pone.0268073.g011
CBB-G250 (Bio-Rad, Hercules, CA, USA), followed by spot excision and identification using matrix-assisted laser desorption/ionization time-of-flight/time-of-flight (MALDI TOF/TOF) mass spectrometry (MS; Bruker Daltonics, Bremen, Germany).

MALDI TOF/TOF protein identification

Spots of interests were cut from the gel and subjected to reduction, alkylation, and in-gel trypsin digestion as described by Ciereszko et al. [11]. The peptides were concentrated and desalted using Zip-Tip pipette tips (Sigma-Aldrich). Finally peptides were eluted with 1 μL of matrix solution (5 mg of α-cyano-4-hydroxycinnamic acid (CHCA, Bruker Daltonics) in 1 ml of 50% acetonitrile and 0.1% trifluoroacetic acid and spotted directly on a steel MALDI target plate (MT 34 Target Plate Ground Steel, Bruker Daltonics). Additionally, peptide calibration standard (Bruker Daltonics) was spotted following the dried-droplet method with the CHCA matrix for the calibration of mass spectrometer. Peptide calibration standard was composed of a mixture of following peptides with monoisotopic [M+H]+ m/z values: bradykinin 1–7 [757.3992], angiotensin II [1046.5418], angiotensin I [1296.6848], substance P [1347.7354], bombesin [1619.8223], ACTH clip 1–17 [2093.0862], ACTH clip 18–39 [2465.1983] and somatostatin 28 [3147.4710].

Mass spectra were acquired in the range of 500–3500 m/z, using an MALDI TOF AutoFlex Speed TOF/TOF mass spectrometer equipped with a Smartbeam II laser (355 nm, Bruker Daltonics). Operating conditions were as follows: laser frequency = 1000.0 Hz, ion source 1 = 19.10 kV, ion source 2 = 16.80 kV, lens voltage = 7.50 kV, reflector voltage = 20.99 kV, reflector 2 voltage = 9.59 kV, optimised pulsed ion extraction time = 120 ns, matrix suppression = 500 Da and positive reflectron mode was used. The strongest precursors were selected...
for MS/MS analysis with the following operating conditions: detection range = 40–2285 Da, laser frequency = 200.0 Hz, ion source 1 = 6.04 kV, ion source 2 = 5.34 kV, lens voltage = 3.00 kV, reflector voltage = 26.99 kV, reflector 2 voltage = 11.59 kV, lift 1 voltage = 18.96 kV, lift 2 voltage = 4.00 kV, optimised pulsed ion extraction time = 130 ns and positive reflectron mode was used. The MS peptide mass fingerprint (PMF) and fragment mass spectra (MS/MS) from each individual spot were combined and used to search against the National Center for Biotechnology Information *Homo sapiens* database (searched on December 4, 2019) using the Mascot Server (Matrix Science, London, UK) with the following settings: cleavage enzyme, trypsin; max missed cleavages, 2; fragment ion mass tolerance, 0.5 Da; parent ion mass tolerance, 100 ppm; alkylation of cysteine by carbamidomethylation as a fixed modification; and oxidation of methionine as a variable modification. The protein was considered identified if it met the following criteria: 1) data sets were thresholded below 1% protein FDR and 2) the minimum threshold to two uniquely mapping peptides according to Omenn et al. [204]. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE [205] partner repository with the dataset identifier PXD032736 and PXD032962 for ADC and SCC, respectively.

**Verification of 2D-DIGE results by Western blotting**

Western blotting was used to verify the results obtained in the proteomic study. We used the V3 stain-free workflow, which eliminates the need for stripping and reprobing the blot for housekeeping proteins [206]. The expression of three proteins of interest was evaluated in the margin and center of the ADC tumor (plastin, LCP1, lamin, LMNA, and mitochondrial aldehyde dehydrogenase 2, ALDH2) as well as the SCC tumor (cytokeratin 19, KRT19, pyruvate kinase, PKM, and Rho GDP-dissociation inhibitor 2, ARHGDIB). The Western blot was performed as previously described [207] with some modifications. Equal amounts of protein (30 μg) were fractionated on 12% Criterion™ TGX Stain-Free™ Protein Gels (Bio-Rad). After electrophoresis, the gels were activated on a Chemidoc according to the manufacturer’s instructions (Bio-Rad); then, the proteins were transferred to PVDF membranes using a Mini Trans–Biol Cell (Bio-Rad) at 60 V for 90 min. After transfer, a stain-free image of the PVDF membranes for total protein normalization was obtained before the membranes were rinsed briefly in distilled water and blocked with 5% bovine serum albumin (Sigma-Aldrich) and then incubated with primary polyclonal antibodies (Abcam, Cambridge, UK) against LCP1 (1:1000), LMNA (1:500), ALDH2 (1:500), KRT19 (1:500), PKM (1:1000), and ARHGDIB (1:300) overnight at 4˚C. After rinsing the membrane to remove unbound primary antibodies, it was exposed to goat anti-rabbit antibodies (1:5000; Sigma-Aldrich) linked to alkaline phosphatase. The products were visualized by incubation in a solution of alkaline phosphate buffer with the addition of nitro blue tetrazolium (Sigma-Aldrich) and 5-bromo-4-chloro-3-indolyl phosphate (Sigma-Aldrich) in the dark. Antibody-bound proteins were detected by enhanced chemiluminescence using the Chemidoc imaging system (Bio-Rad). All the band intensities were measured with the Image Lab software version 5.2 (Bio-Rad). The image of the gel acquired before transfer was used as a control for unequal protein loading among the samples. The volume density of each target protein band was normalized to its respective total protein content, whereas the total protein band was normalized to the total protein loaded into each lane using stain-free technology, with the data expressed in arbitrary units.

**Functional analysis**

Ingenuity pathway analysis (IPA) software (IPA®, Qiagen, Redwood City, CA, USA) was used to investigate the functional and canonical pathways enriched by the differentially
expressed proteins (http://www.ingenuity.com) and to predict upstream regulators. Fisher’s exact test and Benjamini–Hochberg multiple testing corrections were used to calculate statistical significance (p < 0.05). Protein–protein interaction network and protein–set enrichment analysis were performed using the STRING 11.0 software [208]. The minimum interaction confidence score for the interaction sources was set to 0.7 for all the networks except the center vs. margin comparison for SCC and ADC due to the short gene lists. The interaction confidence for the last two comparisons was set to 0.4. The MCL clustering algorithm was used, with the inflation set to 3.

**Statistical analysis**

Statistical analysis of the changes in protein abundance was performed using the Biological Variance module of the DeCyder Differential Analysis software version 5.02 (GE Healthcare) on 8 and 7 biological replicates corresponding to individual ADC and SCC patients, respectively. Direct comparisons of spot volumes were made between Cy3- or Cy5-labelled samples and the Cy2-labelled pool standard for each gel. The Cy3/Cy2 and Cy5/Cy2 ratios were used to calculate the average changes in abundance. The data were expressed as the log standardized abundance to ensure that the data were normally distributed. One-way ANOVA, t-tests, and average ratio tests were performed; changes in protein spot abundance were considered statistically significant at p < 0.05. For the MS PMF and MS/MS ion search, statistically significant (p ≤ 0.05) matches found by MASCOT were regarded as correct hits. The differences in the expression of verified proteins between the margin and center were analyzed by Student’s t-tests using the GraphPad Prism 5 statistical software (GraphPad Software Inc., San Diego, CA, USA). The data are presented as the means ± SDs.

**Supporting information**

S1 Table. Proteins found to be present in different abundances in the lung cancer of center and margin of ADC tumor in relation to control. (DOCX)

S2 Table. Proteins found to be present in different abundances in the lung cancer of center and margin of SCC tumor in relation to control. (DOCX)

S3 Table. Mixing and dying scheme of ADC lung cancer samples, n = 8 for each group. (DOCX)

S4 Table. Mixing and dying scheme of SCC lung cancer samples, n = 7 for each group. (DOCX)

S1 Material. IPA of ADC. (XLSX)

S2 Material. IPA of SCC. (XLSX)

S3 Material. Enrichment of ADC (center vs. control). (XLSX)

S4 Material. Enrichment of ADC (center vs. margin). (XLSX)
S5 Material. Enrichment of ADC (margin vs. control).
(XLSX)

S6 Material. Enrichment of SCC (center vs. control).
(XLSX)

S7 Material. Enrichment of SCC (center vs. margin).
(XLSX)

S8 Material. Enrichment of SCC (margin vs. control).
(XLS)

S9 Material. Summary of standard operating procedure regulating the process of tissue samples collection in the clinical setting—macroscopic evaluation of resected specimen and the process of microscopic evaluation of fresh frozen and formalin-fixed paraffin-embedded tissue samples.
(DOCX)

S1 Raw images. Uncropped, unadjusted images of western blots.
(PDF)

Acknowledgments
We thank Halina Karol and Ewa Liszewska for excellent technical assistance during the work.

Author Contributions
Conceptualization: Andrzej Ciereszko, Mariola A. Dietrich, Mariola Słowińska, Joanna Nynca, Michał Ciborowski, Monika M. Kaczmarek, Joanna Kiślik, Anna Michalska-Falkowska, Joanna Reszeć, Ewa Sierko, Jacek Nikliński.
Data curation: Monika M. Kaczmarek, Kamil Myszczyński.
Formal analysis: Mariola A. Dietrich.
Funding acquisition: Jacek Nikliński.
Investigation: Mariola A. Dietrich, Mariola Słowińska, Joanna Nynca, Anna Majewska, Natalia Kodzik.
Methodology: Andrzej Ciereszko, Mariola A. Dietrich, Mariola Słowińska, Joanna Nynca, Michał Ciborowski, Joanna Kiślik, Joanna Reszeć.
Project administration: Michał Ciborowski, Monika M. Kaczmarek, Jacek Nikliński.
Software: Monika M. Kaczmarek, Kamil Myszczyński.
Supervision: Andrzej Ciereszko, Jacek Nikliński.
Validation: Mariola A. Dietrich, Mariola Słowińska, Joanna Nynca.
Writing – original draft: Andrzej Ciereszko.
Writing – review & editing: Andrzej Ciereszko, Mariola A. Dietrich, Mariola Słowińska, Joanna Nynca, Michał Ciborowski, Monika M. Kaczmarek.

References
1. Hoseok I, Cho JY. Lung cancer biomarkers. Adv Clin Chem. 2015; 72: 107–170. https://doi.org/10.1016/bs.acc.2015.07.003 PMID: 26471082
1. Daraselia N, Wang Y, Budoff A, Lituev A, Potapova O, Vansant G, et al. Molecular signature and pathway analysis of human primary squamous and adenocarcinoma lung cancers. Am J Cancer Res. 2012; 2: 93–103. PMID: 22206048, pmcid: pmc3238469.

2. Niklinski J, Kretowski A, Moniuszko M, Reszec J, Michalska-Falkowska A, Niemira M, et al. Systematic biobanking, novel imaging techniques, and advanced molecular analysis for precise tumor diagnosis and therapy: The Polish MOBIT project. Adv Med Sci. 2017; 62: 405–413. https://doi.org/10.1016/j. advms.2017.05.002 PMID: 28646744

3. Nolen BM, Langmead CJ, Choi S, Lomakin A, Marrangoni A, Bigbee WL, et al. Serum biomarker profiles as diagnostic tools in lung cancer. Canc Biomark. 2011; 10: 3–12. https://doi.org/10.3233/CBM-2012-0229 PMID: 22297547

4. Zhang H, Guo H, Fan Q, Wu Y. Analysis and identification of tumor markers in lung cancer using two-dimensional gel electrophoresis and matrix-assisted laser desorption ionization time of flight mass spectrometry. Life Sci J. 2009; 6: 46–53.

5. Niemira M, Collin F, Szalkowska A, Bielska A, Chwialkowska K, Reszec J, et al. Molecular signature of subtypes of non-small-cell lung cancer by large-scale transcriptional profiling: Identification of key modules and genes by weighted gene co-expression network analysis (WGCNA). Cancers. 2020; 12: 37. https://doi.org/10.3390/cancers12010037 PMID: 31877723

6. Niemira M, Collin F, Szalkowska A, Bielska A, Chwialkowska K, Reszec J, et al. Molecular signature of subtypes of non-small-cell lung cancer by large-scale transcriptional profiling: Identification of key modules and genes by weighted gene co-expression network analysis (WGCNA). Cancers. 2020; 12: 37. https://doi.org/10.3390/cancers12010037 PMID: 31877723

7. Kisluk J, Ciborowski M, Niemira M, Kretowski A, Niklinski J. Proteomics biomarkers for non-small cell lung cancer. J Pharm Biomed Anal. 2014; 101: 40–49. https://doi.org/10.1016/j.jpba.2014.07.038 PMID: 25175018

8. Ohlendieck K. Comparative DIGE proteomics. Methods Mol Biol. 2018; 1664: 17–24. https://doi.org/10.1007/978-1-4939-7268-5_2 PMID: 29019121

9. Pastor MD, Nogal A, Molina-Pinelo S, Carrero A, Paz-Ares L. Proteomic biomarkers in lung cancer. Clin Transl Oncol. 2013; 15: 671–682. https://doi.org/10.1007/s12094-013-1034-0 PMID: 23606351

10. Kondo T. Cancer biomarker development and two-dimensional difference gel electrophoresis (2D-DIGE). Biochim. Biophys. Acta Proteins Proteom. 2019; 1867: 2–8. https://doi.org/10.1016/j.bbapap.2018.07.002 PMID: 30392560

11. Ciereszko A, Dietrich MA, Słowińska M, Nynca J, Ciborowski M, Kisluk J, et al. Identification of protein changes in the blood plasma of lung cancer patients subjected to chemotherapy using a 2D-DIGE approach. PLoS ONE. 2012; 14: 10. https://doi.org/10.1371/journal.pone.0022840 PMID: 23622403

12. Kow Y, Jo HS, Beo S, Seo Y, Song P, Song M, et al. Application of proteomics in cancer: Recent trends and approaches for biomarkers discovery. Front Med. 2021; 8: 747333. https://doi.org/10.3389/fmed.2021.747333 PMID: 3461760

13. Pedersen S, Jensen KP, Honoré B, Kristensen SR, Pedersen CH, Szejniuk WM, et al. Circulating microvesicles and exosomes in small cell lung cancer by quantitative proteomics. Clin Proteomics. 2022; 19: 2. https://doi.org/10.1186/s12094-021-09342-w PMID: 3496345

14. Advani D, Sharma S, Kumari S, Ambasta RK, Kumar P. Precision oncology, signaling, and anticancer agents in cancer therapeutics. Anticancer Agents Med Chem. 2022; 22: 433–468. https://doi.org/10.1080/14786419.2021.1960401 PMID: 33687887

15. Solis-Fernández G, Montero-Calle A, Martínez-Useros J, López-Janeiro Á, de los Ríos V, Sanz R, et al. Spatial proteomic analysis of isogenic metastatic colorectal cancer cells reveals key dysregulated proteins associated with lymph node, liver, and lung metastasis. Cells. 2022; 11: 447. https://doi.org/10.3390/cells11030447 PMID: 35159257

16. Zhu X, Wang Y, Jiang C, Li X, Sun L, Wang G, et al. Radiosensitivity-specific proteomic and signaling pathway network of non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 2022; 112: 529–541. https://doi.org/10.1016/j.ijrobp.2021.08.041 PMID: 34506873

17. Richter A, Fichtner A, Joost J, Brockmeyer P, Kaufmann P, Schliephake H, et al. Quantitative proteomics identifies biomarkers to distinguish pulmonary from head and neck squamous cell carcinomas by immunohistochemistry. J Pathol Clin Res. 2022; 8: 33–47. https://doi.org/10.1002/cp2.244 PMID: 3464799

18. Baran K, Brzezianska-Lasota E. Proteomic biomarkers of non-small cell lung cancer patients. Adv Respir Med. 2021; 89: 419–426. https://doi.org/10.5603/ARM.a2021.0089 PMID: 34494245
22. Thakur SS, Gowda H, Mani DR, Chatterjee B. Editorial: Proteomics and its applications in cancer. Front Oncol. 2021; 11: 772811. https://doi.org/10.3389/oncology.2021.772811 PMID: 34692554

23. Kadara H, Tran LM, Liu B, Vachani A, Li S, Sinjab A, et al. Early diagnosis and screening for lung cancer. Cold Spring Harbor Perspect Med. 2021; 11: a037994. https://doi.org/10.1101/cshperspect.a037994 PMID: 34001525

24. Fahrmann JF, Katayama H, Iraijzad E, Chakraborty A, Kato T, Mao X, et al. Plasma based protein signatures associated with small cell lung cancer. Cancers (Basel). 2021; 13: 3972. https://doi.org/10.3390/cancers13163972 PMID: 34439128

25. Su M, Zhang Z, Zhou L, Han C, Huang C. Nice EC. Proteomics, personalized medicine and cancer. Cancers (Basel). 2021; 13: 2512. https://doi.org/10.3390/cancers13112577 PMID: 34063807

26. Fumagalli C, Barberis M. Diagnostic and predictive biomarkers in lung cancer. Cancers (Basel). 2021; 13: 2577. https://doi.org/10.3390/cancers13112577 PMID: 34070230

27. Paul D, Chanukuppa V, Reddy PJ, Taunk K, Adhav R, Srivastava S, et al. Global proteomic profiling identifies etoposide chemoresistance markers in non-small cell lung carcinoma. J Proteomics. 2016; 138: 95–105. https://doi.org/10.1016/j.jprot.2016.02.008 PMID: 26898345

28. Youseﬁ Z, Sarvari J, Nakamura K, Kuramitsu Y, Ghaderi A, Mojtahedi Z. Secretomic analysis of large cell lung cancer cell lines using two-dimensional gel electrophoresis coupled to mass spectrometry. Folia Histochem Cytobiol. 2012; 50: 368–374. https://doi.org/10.5603/18762 PMID: 23042266

29. Tan F, Jiang Y, Sun N, Chen Z, Lv Y, Shao K, et al. Identiﬁcation of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis. Mol Cell Proteomics. 2012; 11: M111.008821. https://doi.org/10.1074/mcp.M111.008821 PMID: 22064513

30. Li BZ, Bai HH, Tan FW, Gao YB, He J. Identiﬁcation of peroxiredoxin 6 as a potential lung adenocarcinoma biomarker for predicting chemotherapy response by proteomic analysis. J Biol Regul Homeostatic Agents. 2021; 35: 537–546. https://doi.org/10.23812/20-683-A PMID: 33631924

31. Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C. Intratumor heterogeneity: Seeing the wood by the trees. Sci Transl Med. 2012; 4: 127. https://doi.org/10.1126/scitranslmed.3003854 PMID: 22461637

32. Seoane J, De Mattos-Arruda L. The challenge of intratumour heterogeneity in precision medicine. J Intern Med. (GBR) 2014; 276: 41–51. https://doi.org/10.1111/joim.12240 PMID: 24661605

33. Davis A, Gao R, Navin N. Tumor evolution: Linear, branching, neutral or punctuated? Biochim. Biophys. Acta Rev. Cancer. 2017; 1867: 151–161. https://doi.org/10.1016/j.bbcan.2017.01.003 PMID: 28110020

34. Moriya Y, Niki T, Yamada T, Matsuno Y, Kondo H, Hirohashi S. Increased expression of laminin-5 and its prognostic signiﬁcance in lung adenocarcinomas of small size: An immunohistochemical analysis of 102 cases. Cancer. 2001; 91: 1129–1141. https://doi.org/10.1002/1097-0142(20010315)91:6<1129::aid-癌1109>3.0.co;2-c PMID: 11267958

35. Giatromanolaki A, Sivridis E, Koukourakis MI. Tumour angiogenesis: Vascular growth and survival. APMIS. 2004; 112: 431–440. https://doi.org/10.1111/j.1600-0463.2004.apm11207-0804.x PMID: 15563307

36. Masuda R, Kijima Dr H, Imamura N, Aruga N, Nakazato K, Oiwa K, et al. Laminin-5 chain expression is associated with tumor cell invasiveness and prognosis of lung squamous cell carcinoma. Biomed Res. 2012; 33: 309–317. https://doi.org/10.2220/biomedres.33.309 PMID: 23124251

37. Jia Y, Yong JSL, Asafova A, Garvalov BK, Caputo L, Cordero J, et al. Lamin B1 loss promotes lung cancer development and metastasis by epithelial-mesenchymal transition reveals a migratory/invasive phenotype. J Proteome Res. 2006; 5: 1143–1154. https://doi.org/10.1021/pr050455t PMID: 16674103

38. Keshavmoumi VG, Michaelidis G, Grasso CS, Anthwal S, Strahler JR, Walker A, et al. Differential protein expression proﬁling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype. J Proteome Res. 2006; 5: 1143–1154. https://doi.org/10.1021/pr050455t PMID: 16674103

39. Clucas J, Valderrama F. ERM proteins in cancer progression. J Cell Sci. 2014; 127: 267–275. https://doi.org/10.1242/jcs.133108 PMID: 24421310
Singh CK, George J, Chhabra G, Nihal M, Chang H, Ahmad N. Genetic manipulation of sirtuin 3.

Nigro E, Imperlini E, Scudiero O, Monaco ML, Polito R, Mazzarella G, et al. Differentially expressed genes in breast cancer cell lines. PLoS ONE. 2017; 12: 11. https://doi.org/10.1371/journal.pone.0239724 PMID: 2912949

Chen X, Liu H, Onaitis MW, Liu Z, Owzar K, Han Y, et al. Polymorphisms of the centrosomal gene and centrosome abnormalities in lung cancer. J Nat Canc Inst. 2001; 93: 1886–1888. https://doi.org/10.1093/jnci/93.24.1886 PMID: 11752014

Kang X, Liu H, Onaitis MW, Liu Z, Owzar K, Han Y, et al. Polymorphisms of the centrosomal gene (FGFR1OP) and lung cancer risk: A meta-analysis of 14463 cases and 44188 controls. Carcinogenesis. 2016; 37: 280–289. https://doi.org/10.1093/carcin/bgw014 PMID: 26905588

Peláez R, Pariente A, Pérez-Sala Á, Larrayoz IM. Integrins: Moonlighting proteins in invasome formation. Cancers. 2019; 11: 5. https://doi.org/10.3390/cancers11050615 PMID: 31052560

Sala M, Ros M, Saltel F. A complex and evolutive character: Two face aspects of ECM in tumor progression. Front Oncol. 2020; 10: 1620. https://doi.org/10.3389/fonc.2020.01620 PMID: 32984031

Li Y, Huang J, Sun J, Xiang S, Yang D, Ying X, et al. The transcription levels and prognostic values of TUBB. J Proteome Res. 2011; 10: 269–276. https://doi.org/10.1021/pr100714b PMID: 21047053

Verano-Braga T, Gorshkov V, Munthe S, Sørensen MD, Kristensen BW, Kjeldsen F. SuperQuant-assisted comparative proteome analysis of glioblastoma subpopulations allows for identification of potential novel therapeutic targets and cell markers. Oncotarget. 2018; 9: 9400–9414. https://doi.org/10.18632/oncotarget.24321 PMID: 29507698

Boccellino M, Pinto F, Ieluzzi V, Giovanni A, Quagliuolo L, Fariello C, et al. Proteomics analysis of human serum of patients with non-small-cell lung cancer reveals proteins as diagnostic biomarker candidates. J Cell Physiol. 2019; 234: 23798–23806. https://doi.org/10.1002/jcp.28948 PMID: 31180588

Singh CK, George J, Chhabra G, Nihal M, Chang H, Ahmad N. Genetic manipulation of sirtuin 3 causes alterations of key metabolic regulators in melanoma. Front Oncol. 2021; 11: 676077. https://doi.org/10.3389/fonc.2021.676077 PMID: 33937086

Verano-Braga T, Gorshkov V, Munthe S, Sørensen MD, Kristensen BW, Kjeldsen F. SuperQuant-assisted comparative proteome analysis of glioblastoma subpopulations allows for identification of potential novel therapeutic targets and cell markers. Oncotarget. 2018; 9: 9400–9414. https://doi.org/10.18632/oncotarget.24321 PMID: 29507698

Buchan SL, Fallatah M, Thirdborough SM, Taraban VY, Rogel A, Thomas L, et al. PD-1 blockade and CD27 stimulation activate distinct transcriptional programs that synergize for CD8+ T-cell-driven antitumor immunity. Clin Cancer Res. 2018; 24: 2383–2394. https://doi.org/10.1158/1078-0432.CCR-17-3057 PMID: 29514845

Rong D, Lin X, Luo Y, Mok TS, Wang Q, Wang H, et al. Identification of the differentially expressed proteins in nasopharyngeal carcinoma by proteomics. Transl Cancer Res. 2020; 9: 21–29. https://doi.org/10.21037/tcr.2019.11.14 PMID: 35117154
62. Pardo I, Lillemoe HA, Blosser RJ, Choi M, Sauder CA, Doxey DK, et al. Komen for the cure tissue bank at the IU Simon Cancer Center. Next-generation transcriptome sequencing of the premenopausal breast epithelium using specimens from a human breast tissue bank. Breast Cancer Res. 2014; 16: R26. https://doi.org/10.1186/bcr3627 PMID: 24636070

63. Singh CK, Chhabra G, Ndiaye MA, Siddiqui IA, Panackal JE, Mintie CA, et al. Quercetin-resveratrol combination for prostate cancer management in TRAMP mice. Cancers (Basel). 2020; 12: 2141. https://doi.org/10.3390/cancers12082141 PMID: 32748838

64. Wei Q, Jiang H, Xiao Z, Baker A, Young MR, Veenstra TD, et al. Sulfiredoxin-peroxiredoxin IV axis promotes human lung cancer progression through modulation of specific phosphokinase signaling. PNAS. 2011; 108: 7004–7009. https://doi.org/10.1073/pnas.1013012108 PMID: 21487000

65. Petrelli F, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V, et al. Prognothic role of lactate dehydrogenase in solid tumors: A systematic review and meta-analysis of 76 studies. Acta Oncol. 2015; 54: 961–970. https://doi.org/10.3109/0284186X.2015.1043026 PMID: 25984930

66. Zheng X, Wang K, Xu L, Ye P, Cai S, Lu H, et al. The effect of serum lactate dehydrogenase levels on lung cancer prognosis: A meta-analysis. Int J Clin Exp Med. 2017; 10: 14179–14186. https://doi.org/10.3109/0284186X.2015.1043026 PMID: 25984930

67. Liu J, Zhu H, Jiang H, Zhang H, Wu D, Hu X, et al. Tumor M2 pyruvate kinase in diagnosis of nonsmall cell lung cancer: A meta-analysis based on Chinese population. J Canc ResTherap. 2015; 11: C104–C106. https://doi.org/10.4103/0973-1482.163857 PMID: 26323904

68. Guo CY, Zhu Q, Tou FF, Wen XM, Kuang YK, Hu H. The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma. BMC Cancer. 2019; 19: 1. https://doi.org/10.1186/s12885-018-5219-3 PMID: 30606139

69. Dajon M., Iribarren K., Petitprez F., Marmier S., Lupo A., Gillard M, et al. Toll like receptor 7 expressed by malignant cells promotes tumor progression and metastasis through the recruitment of myeloid derived suppressor cells. Oncoimmunology. 2019; 8: 1. https://doi.org/10.1080/2162402X.2018.1505174 PMID: 30546943

70. Zhang W, Wei Y, Ignatchenko V, Li L, Sakashita S, Pham NA, et al. Proteomic profiles of human lung adenocarcinoma and squamous cell carcinoma using super-SILAC and label-free quantification approaches. Proteomics. 2014; 14: 795–803. https://doi.org/10.1002/pmic.201300382 PMID: 24455208

71. Kim KM, An AR, Park HS, Jang KY, Moon WS, Kang MJ, et al. Combined expression of protein disulfide isomerase and endoplasmic reticulum oxidoreductin 1 α is a poor prognostic marker for non-small cell lung cancer. Oncol Lett. 2016; 16: 5753–5760. https://doi.org/10.3892/ol.2016.5339 PMID: 30344729

72. Lu H, Meng Q, Wen Y, Hu J, Zhao Y, Cai L. Increased EHD1 in non-small cell lung cancer predicts poor survival. Thoracic Cancer. 2013; 4: 422–432. https://doi.org/10.1111/1759-7714.12043 PMID: 28920217

73. Gao Y, Wang Y, Sun L, Meng Q, Cai L, Dong X. Expression of TGFβ-1 and EHD1 correlated with survival of non-small cell Lung cancer. Tumor Biol. 2014; 35: 9371–9380. https://doi.org/10.1007/s13277-014-2164-x PMID: 24946721

74. Meng Q, Sun W, Li M, Zhao Y, Chen X, Sun L, et al. Increased expression of Eps15 homology domain 1 is associated with poor prognosis in resected small cell lung cancer. J Cancer. 2015; 6: 990–995. https://doi.org/10.7150/jca.11650 PMID: 26366212

75. Wang B, Chen S, Zhao JQ, Xiang BL, Gu X, Zou F, et al. ADAMTS-1 inhibits angiogenesis via the PI3K/Akt-VEGF pathway in lung cancer cells. Transl Cancer Res. 2019; 8: 2725–2735. https://doi.org/10.21037/tcr.2019.10.34 PMID: 35117030

76. Wang T, Xing Y, Meng Q, Lu H, Liu W, Yan S, et al. Mammalian Eps15 homology domain 1 potentiates angiogenesis of non-small cell lung cancer by regulating s2AR signaling. J Exp Clin Cancer. 2019; 38: 174. https://doi.org/10.1186/s13046-019-1162-7 PMID: 31023336

77. Guo H, Zhang XY, Peng J, Huang Y, Yang Y, Liu Y, et al. RUVBL1, a novel C-RAF-binding protein, activates the RAF/MEK/ERK pathway to promote lung cancer tumorigenesis. Biochem Biophys Res Commun. 2018; 498: 932–939. https://doi.org/10.1016/j.bbrc.2018.03.084 PMID: 29545175

78. Lou X, Xiao T, Zhao K, Wang H, Zheng H, Lin D, et al. Cathepsin D is secreted from M-BE cells: Its potential role as a biomarker of lung cancer. J Proteome Res. 2007; 6: 1083–1092. https://doi.org/10.1021/pr060422t PMID: 17284061

79. Nickolich M., Dowlati A. Prognostic markers in small cell lung cancer. Current Cancer Therapy Rev. 2014; 10: 39–46.

80. Mimae T, Tsuta K, Maeshima AM, Okada M, Asamura H, Kondo T, et al. Cathepsin D as a potential prognostic marker for lung adenocarcinoma. Pathol Res Pract. 2012; 208: S34–S40. https://doi.org/10.1016/j.prp.2012.05.020 PMID: 22824147

81. Niu H, Li H, Xu C, He P. Expression profile of RhoGDI2 in lung cancers and role of RhoGDI2 in lung cancer metastasis. Oncol Rep, 2010; 24: 465–471. https://doi.org/10.3892/or_00000880 PMID: 20596634
82. Niu H, Wu B, Peng Y, Jiang H, Zhang Y, Wang J, et al. RNA interference-mediated knockdown of RhoGD12 induces the migration and invasion of human lung cancer A549 cells via activating the PI3K/Akt pathway. Tumor Biol. 2014; 36: 409–419. https://doi.org/10.1007/s13277-014-2671-9 PMID: 25266803

83. Xie X, Lian S, Zhou Y, Li B, Lu Y, Yeung I, et al. Tumor-derived exosomes can specifically prevent cancer metastatic organotropism. J. Control Release. 2021; 331: 404–415. https://doi.org/10.1016/j.jconrel.2021.01.030 PMID: 33485883

84. McAndrews KM, Kalluri R. Mechanisms associated with biogenesis of exosomes in cancer. Mol Cancer. 2019; 18: 1. https://doi.org/10.1186/s12943-018-0930-x PMID: 30609930

85. Suhail Y, Cain MP, Vanaja K, Kurywchak PA, Levchenko A, Kalluri R, et al. Systems biology of cancer metastasis. Cell Syst. 2019; 9: 109–127. https://doi.org/10.1016/j.cels.2019.07.003 PMID: 31465728

86. Shushkova NA, Novikova SE, Zgoda VG. Exosomes of malignant tumors: Prospects of omics diagnostics. Biomed Khim. 2019; 65: 457–467. https://doi.org/10.18097/PBMC20196506457 PMID: 31876516

87. Svensmark JH, Brakebusch C. Rho GTPases in cancer: Friend or foe? Oncogene. 2019; 38: 7447–7456. https://doi.org/10.1038/s41388-019-0963-7 PMID: 31427738

88. Han Y, Wu Y, Gao S, Xu Y, Guan Z, Qiu X, et al. Expression and clinical significance of RhoC and RhoGDla in non-small cell lung cancer. Chin J Lung Cancer. 2008; 11: 391–397. https://doi.org/10.3779/j.issn.1009-3419.2008.03.007 PMID: 20731941

92. Castro-Rivera E, Ran S, Brekken RA, Minna JD. Semaphorin 3B inhibits the phosphatidylinositol 3-kinase/Akt pathway through neuropilin-1 in lung and breast cancer cells. Cancer Res. 2008; 68: 8295–8303. https://doi.org/10.1158/0008-5472.CAN-07-6601 PMID: 18922901

93. Potiron VA, Roche J, Drabkin HA. Semaphorins and their receptors in lung cancer. Cancer Lett. 2009; 273: 1–14. https://doi.org/10.1016/j.canlet.2008.05.032 PMID: 18625544

94. Neufeld G, Mumblat Y, Smolkin T, Toledano S, Nir-Zvi I, Ziv K, et al. The role of the semaphorins in cancer. Cell Adhesion Migr. 2016; 10: 652–674. https://doi.org/10.1007/19336918.2016.1197478 PMID: 27533782

95. Gurtapu S, Tamagnone L. Semaphorins as regulators of phenotypic plasticity and functional reprogramming of cancer cells. Trends Mol Med. 2019; 25: 303–314. https://doi.org/10.1016/j.molmed.2019.01.010 PMID: 30824197

96. Iyer AS, Chapoval SP. Neuroimmune semaphorin 4A in cancer angiogenesis and inflammation: A promoter or a suppressor? Int J Mol Sci. 2019; 20: 124. https://doi.org/10.3390/ijms20010124 PMID: 30590822

97. Wu Q, Li G, Wen C, Zeng T, Fan Y, Liu C, et al. Monoubiquitination of p120-catenin is essential for TGFβ-induced epithelial-mesenchymal transition and tumor metastasis. Sci Adv. 2020; 6: eaay9819. https://doi.org/10.1126/sciadv.ay9819 PMID: 32010791

98. Venhuizen, JH, Jacobs FJC, Span PN, Zegers MM. P120 and E-cadherin: Double-edged swords in tumor metastasis. Semin Cancer Biol. 2020; 60: 107–120. https://doi.org/10.1016/j.semcancer.2019.07.020 PMID: 31369816

99. Gallo LH, Ko J, Donohue DJ. The importance of regulatory ubiquitination in cancer and metastasis. Cell Cycle. 2017; 16: 634–48. https://doi.org/10.1080/15384101.2017.1288326 PMID: 28166483

100. Fan Q, Wang Q, Cai R, Yuan H, Xu M. The ubiquitin system: Orchestrating cellular signals in non-small-cell lung cancer. Cell Mol Biol. Lett. 2020; 25: 1. https://doi.org/10.1016/j.s11658-019-0193-6 PMID: 31988639

101. Gatti V, Bernassola F, Talora C, Melino G, Peschirolli A. The impact of the ubiquitin system in the pathogenesis of squamous cell carcinomas. Cancers. 2020; 12: 1–24. https://doi.org/10.3390/cancers12061595 PMID: 32560247

102. Xing L, Cheng Q, Zha G, Yi S. Transcriptional profiling at high temporal resolution reveals robust Immune/Inflammatory responses during rat sciatic nerve recovery. Mediators Inflamm. 2017;3827841. https://doi.org/10.1155/2017/3827841 PMID: 28490837
103. Merdad A, Karim S, Schulten HJ, Dallol A, Buhmeida A, Al-Thubaiti F, et al. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer: MMP-9 as a potential biomarker for cancer invasion and metastasis. Anticancer Res. 2014; 34: 1355–1366. PMID: 24596383

104. Zheng ML, Zhou NK, Luo CH. Integrating differential pathway analysis with Monte Carlo cross-validation reveals seed cross-talks in non-small cell lung carcinoma. J BU ON. 2016; 21: 1203–1209. PMID: 27837624

105. Piper M, Mueller AC, Karam SD. The interplay between cancer associated fibroblasts and immune cells in the context of radiation therapy. Mol Carcinog. 2020; 59: 754–765. https://doi.org/10.1002/mc.23205 PMID: 32363633

106. Kaushik N, Kim S, Suh Y, Lee SJ. Proinvasive extracellular matrix remodeling for tumor progression. Arch Pharmacal Res. 2019; 42: 40–47. https://doi.org/10.1007/s12272-018-1097-0 PMID: 30515725

107. Gosetti F, Mazzucco E, Gennaro MC, Marengo E. Simultaneous determination of sixteen undervarized biogenic amines in human urine by HPLC-MS/MS. Anal Bioanal Chem. 2013; 405: 907–916. https://doi.org/10.1007/s00216-012-6269-z PMID: 22842827

108. Dassword M, Ooko E, Efferth T. Collateral sensitivity of parthenolide via NF-κB and HIF-α inhibition and epigenetic changes in drug-resistant cancer cell lines. Front Pharmacol 2019; 10: 542. https://doi.org/10.3389/fphar.2019.00542 PMID: 31164821

109. Dabral S, Muecke C, Valasarajan C, Schmoranzer M, Wietelman A, Semenza GL, et al. A RASSF1 A-HIF1α loop drives Warburg effect in cancer and pulmonary hypertension. Nat Commun. 2019; 10: 2130. https://doi.org/10.1038/s41467-019-10044-z PMID: 31086178

110. Sullivan R, Graham CH. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev. 2007; 26: 319–331. https://doi.org/10.1007/s10555-007-9062-2 PMID: 17458507

111. Kim HJ, Lee HH. L-plasmin: Structure, regulation, and roles in cancer invasion and in macrophages. J Bacteriol Virol. 2018; 48: 175–180. https://doi.org/10.4167/jbv.2018.48.4.175.

112. Cunha LD, Yang M, Carter R, Guy C, Harris L, Crawford JC, et al. LC3-associated phagocytosis in myeloid cells promotes tumor immune tolerance. Cell. 2018; 175: 429,441. e16. https://doi.org/10.1016/j.cell.2018.08.061 PMID: 30245008

113. Advani J, Subbannayya Y, Patel K, Khan AA, Patil AH, Jain A.P, et al. Long-term cigarette smoke exposure and changes in miRNA expression and proteome in non-small-cell lung cancer. OMICS J Integr Biol. 2017; 21: 390–403. https://doi.org/10.1089/omi.2017.0045 PMID: 28692419

114. Yalçın M, El-Athman R, Ouk K, Priller J, Relógio A. Analysis of the circadian regulation of cancer hallmarks by a cross-platform study of colorectal cancer time-series data reveals an association with genes involved in Huntington’s disease. Cancers. 2020; 12: 963. https://doi.org/10.3390/cancers12040963 PMID: 32295075

115. Moreira Sousa C, McGuire JR, Thion MS, Gentien D, de la Grange P, Tezenas du Montcel S, et al. The huntington disease protein accelerates breast tumour development and metastasis through ErbB2/HER2 signalling. EMBO Mol Med. 2013; 5: 309–325. https://doi.org/10.1002/emmm.201201546 PMID: 23300147

116. Taylor KM, Ray DW, Sommer P. Glucocorticoid receptors in lung cancer: New perspectives. J Endocrinol. 2016; 229: R17–28. https://doi.org/10.1530/JEO-15-0496 PMID: 26795718

117. Shi W, Wang D, Yuan X, Liu Y, Guo X, Li J, et al. Glucocorticoid receptor-IRS-1 axis controls EMT and the metastasis of breast cancers. J Mol Cell Biol. 2019; 11: 1042–5105. https://doi.org/10.1093/jmcb/mjz001 PMID: 30726932

118. Matthews LC, Berry AA, Morgan DJ, Poolman TM, Bauer K, Kramer F, et al. Glucocorticoid receptor regulates accurate chromosome segregation and is associated with malignancy. Proc Natl Acad Sci US. 2015; 112: 5479–5484. https://doi.org/10.1073/pnas.1411356112 PMID: 25847991

119. Nikol’skyy VV, Chirvina ED, Tyutyunova AM, Fedenicheva LN. Impaired synthesis of thyroid hormones in lung cancer patients. Vopr Onkol. 1980; 26: 102–104.

120. Davis PJ, Mousa SA, Lin HY. Nongenomic actions of thyroid hormone: The integrin component. Physiol Rev. 2021; 101: 319–352. https://doi.org/10.1152/physrev.00038.2019 PMID: 32584192

121. Schmohl KA, Müller AM, Nelson PJ, Spitzweg C. Thyroid hormone effects on mesenchymal stem cell biology in the tumour microenvironment. Exp Clin Endocr Diab. 2020; 128: 462–468. https://doi.org/10.1055/a-1022-9874 PMID: 31648351

122. Chen YJ, Guo YN, Shi K, Huang HM, Huang SP, Xu WQ, et al. Down-regulation of microRNA-144-3p and its clinical value in non-small cell lung cancer: A comprehensive analysis based on microarray, miRNA-sequencing, and quantitative real-time PCR data. Respir Res. 2019; 20: 48. https://doi.org/10.1186/s12931-019-0994-1 PMID: 30832674
123. Wang C, Zhang J, Yin J, Gan Y, Xu S, Gu Y, et al. Alternative approaches to target Myc for cancer treatment. Signal Transduct Target Ther. 2021; 6: 117. https://doi.org/10.1038/s41392-021-00500-y PMID: 33692331

124. Schaafisma E, Zhao Y, Zhang L, Li Y, Cheng C. MYC Activity inference captures diverse mechanisms of aberrant MYC pathway activation in human cancers. Mol Cancer Res. 2021; 19: 414–428. https://doi.org/10.1158/1541-7786.MCR-20-0526 PMID: 33234576

125. Cuzziol CI, Castanholle-Nunes MMU, Pavarrondo E, Goloni-Bertollo EM. MicroRNAs as regulators of VEGFA and NFE2L2 in cancer. Gene. 2020; 759: 144994. https://doi.org/10.1016/j.gene.2020.144994 PMID: 32721745

126. Jeong Y, Hellyer JA, Stehr H, Hoang NT, Niu X, Das M, et al. Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of patients with non-small cell lung cancer. Clin Cancer Res. 2020; 26: 274–281. https://doi.org/10.1158/1078-0432.CCR-19-1237 PMID: 31548347

127. Xu Z, Xu J, Hu B, Lin B, Cai S, Guo J, et al. LARP1 is regulated by the XIST/miR-374a axis and functions as an oncogene in non-small cell lung carcinoma. Oncol Rep. 2017; 38: 3659–3667. https://doi.org/10.3892/or.2017.6040 PMID: 29039571

128. Mura M, Hopkins TG, Michael T, Abd-Latip N, Weir J, Aboagye E, et al. LARP1 post-transcriptionally regulates mTOR and contributes to cancer progression. Oncogene. 2015; 34: 5025–5036. https://doi.org/10.1038/onc.2014.428 PMID: 25531318

129. Wang HJ, Pochampalli M, Wang LY, Zou JX, Li PS, Hsu SC, et al. KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC. Oncogene. 2019; 38: 17–32. https://doi.org/10.1038/s41388-018-0414-x PMID: 30072740

130. Qu LH, Fang Q, Yin T, Yi HM, Mei GB, Hong ZZ, et al. Comprehensive analyses of prognostic biomarkers and immune infiltrates among histone lysine demethylases (KDMs) in hepatocellular carcinoma. Cancer Immunol Immunother. 2022; 7. https://doi.org/10.1007/s00262-022-03167-8 PMID: 35254477

131. Kim I, Park JW. Hypoxia-driven epigenetic regulation in cancer progression: A focus on histone methylation and its modifying enzymes. Cancer Lett. 2020; 489: 41–49. https://doi.org/10.1016/j.canlet.2020.05.025 PMID: 32522693

132. Khwaja RM, Chu QS. Present and emerging biomarkers in immunotherapy for metastatic non-small cell lung cancer: a review. Curr Oncol. 2022; 29: 479–489. https://doi.org/10.3390/curoncol29020043 PMID: 35200543

133. Cucurull M, Notario L, Sanchez-Cespedes M, Hierro C, Estival A, Carcereny E, et al. Targeting KRAS in lung cancer beyond KRAS G12C inhibitors: The immune regulatory role of KRAS and novel therapeutic strategies. Front Oncol. 2022; 11: 793121. https://doi.org/10.3389/fonc.2021.793121 PMID: 35096591

134. Ricciuti B, Arbour KC, Lin JJ, Vajdi A, Vokes N, Hong L, et al. Diminished efficacy of programmed death--(Ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status. J Thorac Oncol. 2022; 17: 399–410. https://doi.org/10.1016/j.jtho.2021.10.013 PMID: 34740862

135. Ishizawa J, Zarabi SF, Davis RE, Halgas O, Nii T, Jitkova Y, et al. Mitochondrial ClpP-mediated proteolysis induces selective cancer cell lethality. Cancer Cell. 2019; 35: 721-737.e9. https://doi.org/10.1016/j.ccell.2019.03.014 PMID: 31056399

136. Nouri K, Feng Y, Schimmer AD. Mitochondrial ClpP serine protease-biological function and emerging target for cancer therapy. Cell Death Dis. 2020; 11: 841. https://doi.org/10.1038/s41419-020-03062-z PMID: 33037181

137. Huang J, Lou J, Liu X, Xie Y. LncRNA PCGsEM1 contributes to the proliferation, migration and invasion of non-small cell lung cancer cells via acting as a sponge for miR-152-3p. Curr Pharm Des. 2021; 27: 4663–4670. https://doi.org/10.2174/138161282766210827104828 PMID: 34455968

138. Weng L, Qiu K, Gao W, Shi C, Shu F. LncRNA PCGEM1 accelerates non-small cell lung cancer progression via sponging miR-433-3p to upregulate WTA5. BMC Pulm Med. 2020; 20: 213. https://doi.org/10.1186/s12890-020-01240-5 PMID: 32787827

139. Wen H, Feng H, Ma Q, Liang C. LncRNA PCGEM1 induces proliferation and migration in non-small cell lung cancer cells through modulating the miR-590-3p/3OSX11 axis. BMC Pulm Med. 2021; 21: 234. https://doi.org/10.1186/s12890-021-01600-9 PMID: 34261474

140. Krämer A, Green J, Pollard J Jr, Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics. 2014; 30: 523–530. https://doi.org/10.1093/bioinformatics/btt703 PMID: 24336805

141. Deligiorgi MV, Trafalis DT. The intriguing thyroid hormones-lung cancer association as exemplification of the thyroid hormones-cancer association: three decades of evolving research. Int J Mol Sci. 2021; 23: 436. https://doi.org/10.3390/ijms23010436 PMID: 35008863
142. Zhu B, Qu S. The relationship between diabetes mellitus and cancers and its underlying mechanisms. Front Endocrinol (Lausanne). 2022; 13: 800995. https://doi.org/10.3389/fendo.2022.800995 PMID: 35222270
143. Van Dyke AL, Cote ML, Wenzlaff AS, Chen W, Abrams J, Land S, et al. Cytokine and cytokine receptor single-nucleotide polymorphisms predict risk for non-small cell lung cancer among women. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1829–1840. https://doi.org/10.1158/1055-9965.EPI-08-0962 PMID: 19505916
144. Kubo H, Mensurado S, Gonçalves-Sousa N, Serre K, Silva-Santos B. Primary tumors limit metastasis formation through induction of IL15-mediated cross-talk between patrolling monocytes and NK cells. Cancer Immunol Res. 2017; 5: 812–820. https://doi.org/10.1158/2326-6066.CIR-17-0082 PMID: 28811289
145. Sathish V, Martin YN, Prakash YS. Sex steroid signaling: implications for lung diseases. Pharmacol Ther. 2015; 150: 94–108. https://doi.org/10.1016/j.pharmthera.2015.01.007 PMID: 25595323
146. Siegfried JM. Smoking out reproductive hormone actions in lung cancer. Mol Cancer Res. 2014; 12: 24–31. https://doi.org/10.1158/1541-7786.MCR-13-0580 PMID: 24398390
147. Siegfried JM, Stabile LP. Estrogenic steroid hormones in lung cancer. Semin Oncol. 2014; 41: 5–16. https://doi.org/10.1053/j.semonc.2013.12.009 PMID: 24565577
148. Liau CS, Morgan P, Thomas W. Oestrogen actions contribute to female gender-specific risks in the development of lung carcinoma. J Steroid Biochem Mol Biol. 2021; 208: 105786. https://doi.org/10.1016/j.jsbmb.2020.105786 PMID: 33189851
149. Musial C, Zaucha R, Kuban-Jankowska A, Konieczna L, Belka M, Marino Gammazza A, et al. Plausible role of estrogens in pathogenesis, progression and Therapy of lung cancer. Int J Environ Res Public Health. 2021; 18: 648. https://doi.org/10.3390/ijerph18020648 PMID: 33466597
150. Turroni S, Tolomeo M, Mamone G, Picariello G, Giacomin E, Brigidi P, et al. A natural-like synthetic small molecule impairs bcr-abl signaling cascades and induces megakaryocyte differentiation in erythroleukemia cells. PLoS One. 2013; 8: e57650. https://doi.org/10.1371/journal.pone.0057650 PMID: 23460890
151. Karthikeyan C, Mallar R, Ashby CR Jr, Amawi H, Abbott KL, Moore J, et al. Pyrimido[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells. Cancer Lett. 2016; 376: 118–26. https://doi.org/10.1016/j.canlet.2016.03.030 PMID: 27012188
152. Guo Y, Luo Y, Zhang Q, Huang X, Li Z, Shen L, et al. First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial. Eur J Cancer. 2021; 156: 35–45. https://doi.org/10.1016/j.ejca.2021.06.039 PMID: 34418685
153. Karia PS, Azzi JR, Heher EC, Hills VM, Schmults CD. Association of sirolimus use with risk for skin cancer in a mixed-organ cohort of solid-organ transplant recipients with a history of cancer. JAMA Dermatol. 2016; 152: 533–540. https://doi.org/10.1001/jamadermatol.2015.5548 PMID: 26792250
154. Rizell M, Andersson M, Cahlín C, Hafström L, Olausson M, Lindner P. Effects of the mTOR inhibitor sirolimus in patients with hematocellular and cholangiocellular cancer. Int J Clin Oncol. 2008; 13: 66–70. https://doi.org/10.1007/s10147-007-0733-3 PMID: 18307022
155. Zou J, Guo P, Lv N, Huang D. Lipopolysaccharide-induced tumor necrosis factor-α factor enhances inflammation and is associated with cancer (Review). Mol Med Rep. 2012; 15: 6399–6404. https://doi.org/10.3892/mmr.2015.4243 PMID: 26324337
156. Kadara H, Schroeder CP, Lotan D, Pisano C, Lotan R. Induction of GDF-15/NAG-1/MIC-1 in human lung carcinoma cells by retinoid-related molecules and assessment of its role in apoptosis. Cancer Biol Ther. 2006; 5: 518–622. https://doi.org/10.4161/ctb.5.5.2602 PMID: 16582595
157. Aouad P, Saikali M, Abdel-Samad R, Fostok S, El-Houjeiri L, Pisano C, et al. Antitumor activities of the synthetic retinoid ST1926 on primary effusion lymphoma in vitro and in vivo models. Cancer Drugs. 2017; 28: 757–770. https://doi.org/10.1007/s10555-017-0632-z PMID: 28471809
158. Karam L, Houshaymi B, Abdel-Samad R, Jaafar M, Halloumi I, Pisano C, et al. Antitumor activity of the synthetic retinoid ST1926 on primary effusion lymphoma in vitro and in vivo models. Oncol Rep. 2018; 39: 721–730. https://doi.org/10.3892/or.2017.6317 PMID: 29207182
159. Toma S, Raffo P, Isnardi L, Palumbo R. Retinoids in lung cancer chemoprevention and treatment. Ann Oncol. 1999; 5: S95–102. https://doi.org/10.1093/annonc/5.s95 PMID: 10582149
160. Sun SY, Yue P, Chen X, Hong WK, Lotan R. The synthetic retinoid CD437 selectively induces apoptosis in human lung cancer cells while sparing normal human lung epithelial cells. Cancer Res. 2002; 62: 2430–2436. PMID: 11956107
161. Han T, Goralski M, Capota E, Padrick SB, Kim J, Xie Y, et al. The antitumor toxin CD437 is a direct inhibitor of DNA polymerase α. Nat Chem Biol. 2016; 12: 511–515. https://doi.org/10.1038/nchembio.2082 PMID: 27182663
162. Zhang Y, Munday R. Dithiolethiones for cancer chemoprevention: where do we stand? Mol Cancer Ther. 2008; 7: 3470–3479. https://doi.org/10.1158/1535-7163.MCT-08-0625 PMID: 19001432

163. Urano Y, Mori C, Fuji A, Konno K, Yamamoto T, Yashirogi S, et al. 6-Hydroxydopamine induces secretion of PARK7/DJ-1 via autophagy-based unconventional secretory pathway. Autophagy, 2018; 14: 1943–1958. https://doi.org/10.1080/15548627.2018.1493043 PMID: 30112966

164. Koukourakis MI, Giatromanolaki A, Thorpe PE, Brekken RA, Sivridis E, Kakolyris S, et al. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res. 2000; 60: 3088–3095. PMID: 10850461

165. González LO, González-Reyes S, Marín L, González L, González JM, Lamelas ML, et al. Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intra-tumour stromal mononuclear inflammatory cells and those at the invasive front of breast carcinomas. Histopathology. 2010; 57: 862–876. https://doi.org/10.1111/j.1365-2559.2010.03723.x PMID: 21166700

166. Hanash S, Taguchi A, Wang H, Ostrin EJ. Deciphering the complexity of the cancer proteome for diagnostic applications. Expert Rev Mol Diagn. 2016; 16: 399–405. https://doi.org/10.1586/14737199.2016.1135738 PMID: 26694525

167. Dubey M, Singh AK, Awasthi D, Nagarkoti S, Kumar S, Ali W, et al. L-plastin S-glutathionylation promotes reduced binding to β-actin and affects neutrophil functions. Free Radic Biol Med. 2015; 86: 1–15. https://doi.org/10.1016/j.freeradbiomed.2015.04.006 PMID: 25881549

168. Oshita F, Morita A, Ito H, Kameda Y, Tsuchiya E, Asai S, et al. Proteomic screening of completely resected tumors in relation to survival in stage I non-small cell lung cancer. Oncol Rep. 2010; 24: 637–645. https://doi.org/10.3892/or_00000902 PMID: 20664968

169. Di Fiore A, Supuran CT, Scaloni A, De Simone G. Human carbonic anhydrases and post-translational modifications: A hidden world possibly affecting protein properties and functions. J Enz Inhib Med Chem. 2020; 35: 1450–1461. https://doi.org/10.1080/14756366.2020.1781846 PMID: 32648529

170. Büchler R, Wendler S, Muckova P, Großkreutz J, Rhode H. The intricacy of biomarker complexity—the identification of a genuine proteomic biomarker is more complicated than believed. Proteomics Clin Appl. 2016; 10: 1073–1076. https://doi.org/10.1002/prca.201600067 PMID: 27377180

171. Zheng Y, Miyamoto DT, Wittner BS, Sullivan JP, Aceto N, Jordan NV, et al. Expression of β-globin by cancer cells promotes cell survival during blood-borne dissemination. Nat Commun. 2017; 8: 14344. https://doi.org/10.1038/ncomms14344 PMID: 28181495

172. López-Sánchez LM, Jurado-Gámez B, Feu-Collado N, Valverde A, Cañas A, Fernández-Rueda JL, et al. Exhaled breath condensate biomarkers for the early diagnosis of lung cancer using proteomics. Am J Physiol Lung Cell Mol Physiol. 2017; 313: L664–676. https://doi.org/10.1152/ajplung.00119.2017 PMID: 28617961

173. Shi K, Li N, Yang M, Li W. Identification of key genes and pathways in female lung cancer patients who never smoked by a bioinformatics analysis. J Cancer. 2018; 10: 51–60. https://doi.org/10.7150/jca.26908 PMID: 30662525

174. Ponzetti M, Capulli M, Angelucci A, Ventura L, Monache SD, Mercurio C, et al. Non-conventional role of haemoglobin β in breast malignancy. Br J Cancer 2017; 117: 994–1006. https://doi.org/10.1038/bjc.2017.247 PMID: 28677262

175. Morimoto R.I. Cells in stress: Transcriptional activation of heat shock genes. Science 1993; 259: 1409–1410. https://doi.org/10.1126/science.8451637 PMID: 8451637

176. Fang Y, Wang XP, Lin HP, Wang QX. Significance of clinicopathology and expression of heat shock protein 72 in human primary lung carcinomas. Adv Mater Res. 2012; 459: 242–246. https://doi.org/10.4028/www.scientific.net/AMR.459.242

177. Kamath A, Joseph AM, Gupta K, Behera D, Jaiswal A, Dewan R, et al. Proteomic analysis of HEK293 cells expressing non-small cell lung carcinoma associated epidermal growth factor receptor variants reveals induction of heat shock response. Exp Hematol Oncol. 2015; 4: 16. https://doi.org/10.1186/s40164-015-0010-5 PMID: 26146591

178. Chen B, Piel WH, Gui L, Bruford E, Monteiro A. The HSP90 family of genes in the human genome: Insights into their divergence and evolution. Genomics. 2005; 86: 627–637. https://doi.org/10.1016/j. ygeno.2005.08.012 PMID: 16289234

179. Wu M, Tu T, Huang Y, Cao Y. Suppression subtractive hybridization identified differentially expressed genes in lung adenocarcinoma: ERGIC3 as a novel lung cancer-related gene. BMC Cancer. 2013; 13: 44. https://doi.org/10.1186/1471-2407-13-44 PMID: 23374247

180. Xu YR, Chen ZW, Zhang GH, Xi YF, Sun RF, Wang XG, et al. HSP90B1 overexpression predicts poor prognosis in NSCLC patients. Tumor Biol. 2016; 37: 14321–14328. https://doi.org/10.1007/s13277-016-5304-7 PMID: 27599983
181. Duan XF, Xin YW. Overexpression of molecule GRP94 favors tumor progression in lung adenocarcinoma by interaction with regulatory T cells. Thorac Cancer. 2020; 11: 704–712. https://doi.org/10.1111/1759-7714.13321 PMID: 31970893

182. Klimczak M, Bieczek P, Zylcz M, Zylcz M. Heat shock proteins create a signature to predict the clinical outcome in breast cancer. Sci Rep. 2019; 9:7507. https://doi.org/10.1038/s41598-019-43556-1 PMID: 31101846

183. Abbas W, Kumar A, Herbein G. The eEF1A proteins: At the crossroads of oncosogenesis, apoptosis, and viral infections. Front Oncol. 2015; 5: 75 https://doi.org/10.3389/fonc.2015.00075 PMID: 25905039

184. Hassan MK, Kumar D, Naik M, Dixit M. The expression profile and prognostic significance of eukaryotic translation elongation factors in different cancers. PLoS ONE. 2018; 13:e0191377. https://doi.org/10.1371/journal.pone.0191377 PMID: 29342219

185. Cristiano L. EEF1G (eukaryotic translation elongation factor 1 gamma). Atlas Genet Cytogenet Oncol Haematol. 2020; 24: 58–68. https://doi.org/10.4267/2042/70656

186. Oji Y, Tatsumi N, Fukuda M, Nakatsuka S, Aoyagi S, Hirata E, et al. The translation elongation factor eEF2 is a novel tumor-associated antigen overexpressed in various types of cancers. Int J Oncol. 2014; 44: 1461–1469. https://doi.org/10.3892/ijo.2014.2318 PMID: 24589652

187. Wang R, Cai Y, Zhang B, Wu Z. A 16-gene expression signature to distinguish stage I from stage II lung squamous carcinoma. Int J Mol Med. 2018; 41: 1377–1384. https://doi.org/10.3892/ijmm.2017.3332 PMID: 29286069

188. Kratzke RA. Targeting eukaryotic protein translation in mesothelioma. Transl Lung Cancer Res. 2017; 6: 343–349. https://doi.org/10.21037/tlcr.2017.06.07 PMID: 28713679

189. Yang C, Zhang Y, Du W, Cheng H, Li C. Eukaryotic translation initiation factor 3 subunit g promotes human colorectal cancer. Am J Transl Res. 2019; 11: 612–623. PMID: 30899366

190. Wang W, He J, Lu H, Kong Q, Lin S. KRT8 and KRT19, associated with EMT, are hypomethylated and overexpressed in lung adenocarcinoma and link to unfavorable prognosis. Biosci Rep. 2020; 40: BSR20193468. https://doi.org/10.1042/BSR20193468 PMID: 32519739

191. Liu Z, Yu S, Ye S, Shen Z, Gao L, Han Z, et al. Keratin 17 activates AKT signalling and induces epithelial-mesenchymal transition in oesophageal squamous cell carcinoma. J Proteomics. 2020; 211:103557. https://doi.org/10.1016/j.jprot.2019.103557 PMID: 31669361

192. Karantza V. Keratins in health and cancer: More than mere epithelial cell markers. Oncogene. 2011; 30: 127–138. https://doi.org/10.1038/onc.2010.456 PMID: 20890307

193. Xie L, Dang Y, Guo J, Sun X, Xie T, Zhang L, et al. High KRT8 expression independently predicts poor prognosis for lung adenocarcinoma patients. Genes. 2019; 10: 36. https://doi.org/10.3390/genes10010036 PMID: 30634629

194. Zhao W, Yang Z, Liu X, Tian Q, Lv Y, Liang Y, et al. Identification of α1-antitrypsin as a potential prognostic biomarker for advanced non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors by proteomic analysis. J Int Med Res. 2013; 41: 573–583. https://doi.org/10.1177/0300060513476582 PMID: 23613495

195. Wei Z, Ma L, Yun S, Chang X. Screening of citrullinated proteins in ten tumor cell lines. Chin J Oncol. 2015; 37: 165–169.

196. Wang J, Jiang D, Li Z, Yang S, Zhou J, Zhang G, et al. BCAP31, a cancer/testis antigen-like protein, can act as a probe for non-small-cell lung cancer metastasis. Sci Rep. 2020; 10: 4025. https://doi.org/10.1038/s41598-020-60905-7 PMID: 32132574

197. Wang K, Li H, Chen R, Zhang Y, Sun XX, Huang W, et al. Combination of CALR and PDIA3 is a potential prognostic biomarker for non-small lung cancer. Oncotarget 2017; 8: 96945–96957. https://doi.org/10.18632/oncotarget.18547 PMID: 29228584

198. Gan Y, Ye F, He XX. The role of YWHAZ in cancer: A maze of opportunities and challenges. J Cancer 2020; 11: 2252–2264. https://doi.org/10.7150/jca.41316 PMID: 32172952

199. Chen CH, Chuang SM, Yang MF, Liao JW, Yu SL, Chen JJ. A novel function of YWHAZ/β-catenin axis in promoting epithelial-mesenchymal transition and lung cancer metastasis. Mol Cancer Res. 2012; 10: 1319–1331. https://doi.org/10.1158/1541-7786.MCR-12-0189 PMID: 22912335

200. Deng Y, Zheng J, Ma J. The clinical and prognostic significance of YWHAZ in non-small-cell lung cancer patients: Immunohistochemical analysis. J Cell Biochem. 2019; 120: 6290–6298. https://doi.org/10.1002/jcb.27915 PMID: 30378158

201. Mantovani A. Cancer: Inflaming metastasis. Nature. 2009; 457: 36–37. https://doi.org/10.1038/457036b PMID: 19122629

202. Meijer TW, Kaanders JH, Span PN, Bussink J. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res. 2012; 18: 5585–5594. https://doi.org/10.1158/1078-0432.CCR-12-0868 PMID: 23071360
203. McAndrews KM, LeBleu VS, Kalluri R. SIRT1 regulates lysosome function and exosome secretion. Dev Cell. 2019; 49: 302–330. https://doi.org/10.1016/j.devcel.2019.04.024 PMID: 31063745

204. Omenn GS, Lane L, Lundberg EK, Beavis RC, Nesvizhskii AI, Deutsch EW. Metrics for the human proteome project 2015: progress on the human proteome and guidelines for high-confidence protein identification. J Proteome Res. 2015; 14: 3452–3460. https://doi.org/10.1021/acs.jproteome.5b00499 PMID: 26155816

205. Vizcaíno JA, Csordas A, del-Toro N, Dianes JA, Griss J, Lavidas I, et al. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res. 2016; 44: 11033. https://doi.org/10.1093/nar/gkw880 PMID: 27683222

206. Posch A, Kohn J, Oh K, Hammond M, Liu N. V3 stain-free workflow for a practical, convenient, and reliable total protein loading control in western blotting. J Visualized Exp. 2013; 82:e50948. https://doi.org/10.3791/50948 PMID: 24429481

207. Repetto O, Mussolin L, Elia C, Martina L, Bianchi M, Buffardi S, et al. Proteomic identification of plasma biomarkers in children and adolescents with recurrent hodgkin lymphoma. J Cancer. 2018; 9: 4650–4658. https://doi.org/10.7150/jca.27560 PMID: 30588249

208. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019; 47: D607–D613. https://doi.org/10.1093/nar/gky1131 PMID: 30476243